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Abstract 
 
Multi-drug tolerance is a phenomenon, in which microorganisms normally susceptible to an antimicrobial agent are able to 
withstand a treatment via phenotypic alteration. The tolerance is conveyed by a microbial subpopulation that is in a non-replicative 
and metabolically inactive state also known as persistence. Through this kind of dormancy, the subpopulation may survive an 
otherwise appropriate course of antimicrobials, since the majority of the drugs target cellular division or metabolism. Upon the 
reduction of the surrounding antimicrobial concentration the multi-drug tolerant cells – persisters –  become resuscitated thus 
allowing repopulation. As opposed to the more widely acknowledged challenge of antimicrobial resistance, the offspring of the 
specialist survivor cells are genetically identical to the susceptible majority. 
 
Persisters are especially abundant in biofilms, a microbial lifestyle characterized by aggregated microcolonies that are covered in a 
self-produced slimy matrix known as extracellular polymeric substance (EPS). Partly owning to this protective matrix, biofilms are 
inherently somewhat tolerant to antimicrobial chemotherapy. Moreover, microbes confined in a biofilm are additionally protected 
against the components of the host immune system. Conversely, it is assumed that persisters in planktonic, i.e. freely floating 
state, are easily cleared out by white blood cells. Combined, the immune evasive properties of biofilms and the remarkable multi-
drug tolerance of persisters give rise to recalcitrant infections that are immensely difficult to eradicate.    
 
The described phenomenon constitutes crucially to the major healthcare challenge of chronic, treatment-resistant infections. 
Tuberculosis, cystic fibrosis lung disorder, bacterial endocarditis and infections related to indwelling medical devices are only a few 
examples of such problems. Despite the need for antimicrobials with anti-persister efficacy, no such therapeutics is available and 
very few are being investigated – one important factor being the lack of relevant drug discovery platforms. Therefore, the aim of 
this study was to develop an anti-persister assay and to carry out a pilot screening of natural product derived bioactive compounds. 
 
Based on the notion that persisters are enriched in bacterial cultures that have reached the stationary phase of growth, a persister 
model was designed using Staphylococcus aureus ATCC 25923 as the test strain. The bacteria were grown in liquid cultures until 
they reached the stationary phase and subsequent experimentation was carried out to confirm the tolerant state. After the 
stationary phase persister model was validated, a small pilot screening of natural products was undertaken in the hope of finding 
novel anti-persister activity. Mitomycin C, a cytotoxic drug with an existing anti-cancer indication was assigned as the positive 
control compound because of its previously established anti-persister activity. Since it is common for all of the persister-related 
diseases that the target microorganisms reside within a protective biofilm, an additional assay based on biofilm regrowth was 
designed to characterize the hit compounds on a more clinically relevant platform. 
 
The persister model culture was shown to be tolerant to conventional antibiotics. The re-induction of metabolic activity by diluting 
into fresh medium recovered the antimicrobial susceptibility expectedly. A total of 4 compounds were identified as anti-persister 
hits in the pilot screening campaign. Chromomycin A3, dehydroabietic acid, mithramycin A and oleanolic acid were all able to 
reduce the viable bacterial count in the stationary phase persister model more than 2 logarithmic units at 100 μM. Mithramycin A 
was the most potent, reducing the viability over 6 log units. The model compound mitomycin C reduced the viable counts 5.49 (± 
0.96) logarithmic units. Out of the 4 hits, dehydroabietic acid was selected for the biofilm relapse assay because of its favourable 
biocompatibility properties. It reduced regrowth for the treated biofilms by 4 logarithmic units, thus demonstrating significant 
activity.  
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Tiivistelmä 
 
Monilääketoleranssi (multi-drug tolerance) on ilmiö, jossa antimikrobilääkkeelle herkät mikro-organismit kykenevät sietämään 
lääkehoitoa fenotyyppiään muokkaamalla. Toleranssin aikaansaa jakaantumattomassa ja metabolisesti epäaktiivisessa tilassa 
elävä osapopulaatio. Tämänkaltaisesta horrostilan tuomasta sietokyvystä käytetään nimitystä persistenssi. Sietokykyinen 
osapopulaatio voi selviytyä asianmukaisesti valitusta antimikrobilääkehoidosta, sillä lääkkeiden vaikutus kohdistuu tyypillisesti juuri 
solunjakaantumistoimintoihin tai aineenvaihduntaan. Kun ympäröivä lääkeainepitoisuus kuurin päätyttyä laskee, nämä 
monilääketolerantit solut – persisterit – elpyvät uudelleen kansoittaakseen tuhoutuneen populaation. Toisin kuin paremmin 
tunnetussa antimikrobilääkeresistenssin ilmiössä, näiden erikoistuneiden selviytyjäsolujen jälkeläiset ovat geneettisesti identtisiä 
lääkkeelle herkän osapopulaation kanssa.  
 
Persisterisoluja on erityisen runsaasti biofilmeissä. Biofilmi on yhteen takertuneiden bakteerien muodostama yhdyskunta, joka 
tuottaa ympärilleen tyypillisen, solunulkoisten polymeerien muodostaman limakerroksen (extracellular polymeric substance, EPS). 
Osittain tämän suojaavan liman ansiosta biofilmit ovat itsessään melko sietokykyisiä antimikrobilääkkeille. Lisäksi biofilmissä elävät 
mikrobit ovat erityisen hyvin suojattuja isäntäorganismin immuunijärjestelmää vastaan. Sen sijaan planktoniset, yksittäisinä soluina 
irrallaan kelluvat mikrobisolut ovat helposti valkosolujen hävitettävissä. Biofilmin immunoevasiiviset ominaisuudet yhdistettynä 
persisterien monilääketoleranssiin mahdollistavatkin erittäin vaikeahoitoisten, kroonisten infektioiden kehittymisen. 
 
Kuvattu sietokykymekanismi kroonistuneiden, hoitoon vastaamattomien infektioiden taustalla muodostaa merkittävän terveysuhan. 
Tuberkuloosi, kystisen fibroosin keuhko-ongelmat, bakteeriendokardiitti ja lääkinnällisiin laitteisiin liittyvät infektiot ovat joitakin 
esimerkkejä tällaisista hoidollisista haasteista. Erityisesti persistereihin tepsivien antimikrobilääkkeiden huutavasta tarpeesta 
huolimatta yhtäkään ei ole käytettävissä ja vain harvoja tutkitaan. Soveltuvien lääkekehitysalustojen puute on yksi olennainen syy 
tähän uusien keksintöjen puutteeseen. Sen vuoksi tämän työn tarkoituksena onkin kehittää menetelmä persisterilääkkeiden 
tunnistamiseksi ja tehdä pienen mittakaavan pilottiseulonta luonnontuotteista eristetyille, bioaktiivisille yhdisteille.  
 
Persisterien on havaittu rikastuvan stationäärivaiheen bakteeriviljelmissä. Sen vuoksi persisterimallia ryhdyttiin kehittämään 
Staphylococcus aureus ATCC 25923 -bakteerikannalla, jota kasvatettiin nesteviljelminä staattiseen kasvuvaiheeseen saakka. 
Malliviljelmän lääketoleranssi tutkittiin, minkä jälkeen se altistettiin valikoiduille luonnontuotteille tarkoituksena löytää 
persisteribakteereihin tehoavia yhdisteitä. Positiiviseksi kontrolliksi valittiin mitomysiini C – syöpälääkkeenä käytettävä sytotoksinen 
yhdiste, jonka on aiemmin todettu tuhoavan myös persisteribakteereita. Koska kliinisesti merkittävät persisteri-ilmentymät tavataan 
juuri biofilmeissä, päätettiin lisäksi kehittää kasvun uudelleenkäynnistymistä biofilmistä mittaava menetelmä seulontalöytöjen 
tarkempaan kartoittamiseen hoidollisesti relevanteissa olosuhteissa. 
 
Persisterimalli havaittiin sietokykyiseksi perinteisille antibiooteille. Metabolisen aktiivisuuden uudelleenkäynnistäminen tuoreeseen 
ravinneliuokseen laimentamalla palautti lääkeherkkyyden odotetusti. Seulonta löysi yhteensä 4 persistereihin tehoavaa yhdistettä: 
kromomysiini A3, dehydroabietiinihappo, mitramysiini A ja oleanolihappo kykenivät kaikki laskemaan elävien bakteerien 
lukumäärää persisterimallissa yli 2 logaritmiyksikköä 100 μM pitoisuuksina. Mitramysiini A oli yhdisteistä tehokkain vähentäen 
bakteerilukua yli 6 yksikköä. Malliyhdiste mitomysiini C vähensi elävien bakteerien lukua vastaavasti 5.49 (± 0.96) 
logaritmiyksikköä. Dehydroabietiinihappo valittiin jatkotutkimukseen biofilmin uudelleenkasvukykykokeeseen sen suosiollisen 
toksisuusprofiilin perusteella. Se vähensi uudelleenkasvua hoidetusta biofilmistä 4 logaritmiyksikköä osoittaen siten merkittävää 
aktiivisuutta.  
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1 INTRODUCTION 
Multidrug tolerance is a phenomenon in which bacteria or other microorganisms can 
transiently alter their behaviour to survive virtually any regular antimicrobial treatment 
(Keren et al. 2004a). As opposed to the more widely understood challenge of 
antimicrobial drug resistance, the basis of multidrug tolerance is in phenotypic rather than 
genotypic variability. A stochastically determined, transient subpopulation within a 
microbial community is constantly in a survival-oriented state known as persistence that 
is characterized by slowed-down growth and metabolic inactivity (Balaban et al. 2004). 
The respective cells are termed persisters. An antimicrobial treatment may readily 
eliminate the susceptible majority of cells from such a culture, but the tolerant (persistent) 
phenotypes prevail to be reverted back to the metabolically active, replicative state after 
the stressor has passed (Keren et al. 2004b). A population regrown from the surviving 
persisters is genetically identical to the one previously eradicated. 
When in planktonic i.e. freely floating state, infective persisters are not particularly 
challenging to overcome (Lewis 2007). An accordingly selected antimicrobial treatment 
will eliminate the susceptible bulk of cells, while the immune system clears out the 
remaining persisters. The vast clinical significance of multidrug tolerance arises from 
persister involvement in another singular microbial lifestyle known as biofilms (Lewis 
2001). Biofilms are defined as surface-adherent microbial aggregates that are enclosed 
within a protective layer of self-produced matrix made of extracellular polymeric 
substance (EPS) (Costerton et al. 1999). Biofilm growth is an inherently tolerant lifestyle 
that is encountered in approximately 60-85 % of all infections (Coenye and Nelis 2010). 
The profound tolerance observed in biofilms has been partly attributed to persister cells 
that are markedly enriched in biofilms (Lewis 2001). Biofilms give them additional 
shielding against host defences among other things, which leads to the emergence of 
recalcitrant infections as the multidrug tolerant subcolony is left untouched to reinitiate 
the pathogen population. 
The diverse and plentiful treatment-resistant biofilm infections cause a huge burden on 
healthcare systems (Parsek and Singh 2003; Bryers 2008). Since no available 
antimicrobial can effectively address persister bacteria regardless of the species and 
2 
 
genotypic susceptibility, the need for new generation anti-persister antimicrobials is 
imperious. Nevertheless, the drug discovery research available on biofilm infections let 
alone their persister involvement is still scarce, possibly owning to platform-related 
challenges and the lack of general acknowledgement of the phenomenon. The above-
described scenario motivates this thesis, in which it is aimed to develop a drug discovery 
platform for anti-persister drugs and to discover relevant new activities in natural 
products.  
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2 LITERATURE REVIEW 
2.1 Persisters 
Persisters were first described by Hobby, Meyer, and Chaffee in 1942 and defined two 
years later by Joseph Bigger: the scientists were consistently left with a small 
subpopulation of surviving bacteria when experimenting with otherwise sufficient doses 
of penicillin (Hobby et al. 1942; Wood et al. 2013). The viable cell count would decline 
sharply after initiating treatment, but with some 1 % of the bacteria left alive the growth 
curve would become flattened to form a biphasic killing pattern. When the surrounding 
conditions returned favourable, the descendants of these surviving bacteria would again 
become susceptible to the previously used antibiotic upon starting to grow again without 
demonstrating any specific and heritable mechanism of antimicrobial resistance. 
Even over 70 years after their initial discovery, the true nature of persisters remains 
elusive (Zhang 2014). In contrast to the genotype-associated antimicrobial resistance, 
persistence is a strictly phenotypic phenomenon, which makes it difficult to directly 
characterize. Complex reporter gene systems and microfluidic devices have been adopted 
for persister research, but the main methodologies are still unchanged from the 40’s; the 
susceptible population is eliminated and the remaining bacteria studied (Balaban et al. 
2004; Lechner et al. 2012; Maisonneuve et al. 2013; Cañas-Duarte et al. 2014).      
This type of an antimicrobial tolerance has been eventually linked to a special state of 
dormancy, in which bacteria or other microorganisms living under stressful conditions 
shut down major parts of their cellular machinery and stop multiplying (Lewis 2007). 
These metabolically inactive microbes are very tolerant to antimicrobials that target 
components of cellular division system or depend on active intake into the target cell. The 
persister phenotype is distinct from an endospore – a dormant structure produced by 
several Gram-positive bacteria in starvation – although the two share important functional 
similarities (Pommerville 2014). The goal of both is to ensure the survival of the organism 
over a rough patch of hardened conditions until the environment returns to a favourable 
state. Unlike persisters, however, endospores are morphologically divergent cells formed 
in an asymmetric division.  
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It has since been understood that persisters have an important role in the development of 
recalcitrant, treatment resistant infections (Lewis 2007). The successful 
chemotherapeutic eradication of a bacterial infection is a result of a synergistic interplay 
between antimicrobial drugs and host immune defences. Antimicrobials halt the division 
of bacteria (bacteriostatic drugs) or kill the susceptible majority (bactericidal drugs), 
while the immune system gets rid of the remaining non-growing bacteria and persisters 
that are defenceless against phagocytic activity. Therefore, for the infection to become 
chronic, it has to be able to evade the host defences. In chronic infections this is achieved 
by bacteria taking seat within a protective barrier of a biofilm matrix or in a 
granulomatous lesion (Tufariello et al. 2003; Thurlow et al. 2011).  
2.1.1 Stringent response  
To survive, bacteria must adapt to changes in their growing environment. For this 
purpose, a complex network of signalling pathways has evolved to translate the 
environmental conditions into biomolecular responses. Various environmental stressors 
including heat, acidity, oxidative stress and amino acid starvation lead to an optimization 
of cellular functions that is known as the stringent response (Poole 2012). The key 
mediators for this response are small nucleotide molecules, also known as alarmones, 
including guanosine tetraphosphate and pentaphosphate (ppGpp/pppGpp) that 
accumulate in cells undergoing starvation which leads to an activation of a plethora of 
different pathways and subsequently to a decrease in protein synthesis and reallocation 
of energy resources (Dalebroux and Swanson 2012). This prepares the bacteria to 
surviving in harsh conditions and may eventually cause cells to enter a non-replicative 
dormant state.  
The alarmone (p)ppGpp is produced on nutrient depletion by several proteins dubbed Rel 
(Haseltine and Block 1973). In Gram-negative bacteria the enzyme mostly responsible 
for (p)ppGpp synthesis is named RelA, and it is distinct from the counteracting (p)ppGpp 
hydrolysing enzyme SpoT (Wexselblatt et al. 2012). In Gram-positive bacteria both 
functions are coupled in a single Rel/Spo enzyme, and the family of these stringent 
response proteins is often referred to as RelA/SpoT homologue proteins or RSHs. When 
a bacterium faces stress, its transcriptional machinery is introduced with an accumulation 
of uncharged transfer-RNA molecules that bind to the ribosome but do not carry their 
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amino acids. This stalls the ribosome and encourages the binding of Rel-proteins at the 
site, which upon activation and detachment of enzyme leads to the synthesis of a large 
number of (p)ppGpp and other downstream events culminating in the stringent response. 
2.1.2 Toxin-antitoxin modules 
The decrease in metabolic activity via the stringent response is closely related to 
persistence, and the underlying molecular mechanisms have been studied in parallel. A 
conserved key component between different persister species is toxin-antitoxin or TA 
modules that in fact function as the effectors in stringent response (Wang and Wood 
2011). They are typically modules that consist of a stable toxin molecule that is constantly 
expressed and its labile antitoxin counterpart continuously broken down by several 
different protease enzymes (Unterholzner et al. 2013). Normally the expression of the 
labile antitoxin is sufficient to counterbalance the toxin, thereby rendering it safe. 
However, in the presence of certain signals more of the antitoxin is degraded than is being 
synthetized to replace it, which lets the toxin exert its effect – possibly leading to the 
stringent response and persistence (Figure 1). 
 
Figure 1. The typical toxin-antitoxin module (modified from Hong-Geller and Micheva-
Viteva 2015). The labile antitoxin is normally produced in quantities sufficient for 
blocking the respective toxin. As a part of the bacterial stress response, the antitoxin 
becomes degraded by an increased protease activity. This leads to the accumulation of 
free toxin, since not enough antitoxin is available for countering toxin production. The 
imbalance may result in persistence. 
 
Persistence 
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Although universally found in bacteria, TA-modules have been studied in particular depth 
in Escherichia coli, in which a total of 11 of them are known to exist promoting 
persistence (Germain et al. 2015). In a majority of the TA-modules the toxin effector is 
by nature an mRNase – an endonuclease that cleaves messenger RNA or mRNA before 
it can be translated into a protein at a ribosome (Maisonneuve et al. 2011). This inhibits 
protein synthesis and leads to the reduction of metabolic activity, eventually causing the 
growth arrest associated with the stringent response and persistence (Keren et al. 2004a).  
In mutation experiments carried out with E. coli a specific mutation was found to 
massively increase persister frequency and thus antimicrobial tolerance (Moyed and 
Bertrand 1983). The mutant was named hipA7 after its characteristic high persistence. 
The associated gene hipA with its variably toxic transcription product of the same name 
were later discovered to be a part of a TA module hipBA with the autoregulating antitoxin 
counterpart of the module named HipB. hipA7 was characterized as a gain-of-function 
mutant, in which the interaction between HipA toxin and HipB antitoxin and thus the 
autoregulation of the module is markedly diminished (Schumacher et al. 2009). Studies 
have since linked TA modules with the stringent response, hipBA being a crucial part of 
the above-described activation pathway (Germain et al. 2015). This was already pointed 
out by Korch et al. (2003), who demonstrated that hipA7 mutants lose their outstanding 
ability to form persisters in high frequency when (p)ppGpp synthase RelA is rendered 
inactive. 
Another example of such a regulatory TA-module found in E. coli is IstR1-tisB that 
promotes growth arrest upon SOS signalling – a pathway activated in bacteria by DNA 
damage (Vogel et al. 2004). IstR1 is an antitoxin that is able to neutralize the tisB toxin 
until it becomes downregulated as a part of the SOS-response. tisB is a membrane acting 
toxin that creates pores from inside the bacterial cell which leads to the disruption of the 
proton motive force as the ion gradient over the cell wall is lost (Gurnev et al. 2012). 
Since the synthesis of ATP depends on it, the cell enters growth arrest as ATP depletes.  
The linkage to SOS response emphasizes the importance of IstR1-tisB from the 
perspective of antimicrobial treatment. Widely used broad spectrum antibiotics in the 
fluoroquinolone class exert their bactericidal effect by inhibiting the DNA-targeting 
enzymes gyrase and topoisomerase, which leads to DNA damage and thus provokes SOS 
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response (Phillips et al. 1987). Studies have confirmed that the fluoroquinolone antibiotic 
ciprofloxacin indeed induces persistence and makes the treated culture tolerant to further 
treatments with other antimicrobials as well (Dörr et al. 2010).  
2.1.3 Dynamics 
Although many factors predicting the metabolic state switch into persistent lifestyle have 
been described, the conversion is by nature a stochastic process (Balaban et al. 2004). 
The growth rate of microbial cells is inherently heterogeneous, arguably for the sole 
purpose to support the survival of the population as a whole by having a number of backup 
cells constantly in a tolerant phenotype. 
From single-cell monitoring experiments with an ampicillin challenge Balaban et al.  
(2004) came to the conclusion that the studied E. coli populations had two distinct types 
of persisters: non-growing, slowly resuscitating cells that are introduced in the culture as 
carryovers from the stationary phase inoculum and slow-growing, quickly resuscitating 
cells that are stochastically induced also in an exponentially growing culture. Both 
withstood the exposure to ampicillin (an antibiotic targeting growing cells). 
The alarmone (p)ppGpp has been proposed as the master regulator of phenotype 
switching (Maisonneuve et al. 2013). Using a fluorescent reporter in E. coli these authors 
demonstrated that cells with high level of the alarmone were non-growing and 
exceedingly tolerant to ampicillin. As described above, stochastic fluctuations in the level 
of the alarmone arising from the itself stochastic Rel/Spo activity have been shown to 
activate the persister-inducing TA modules, including HipBA that further elevates 
(p)ppGpp thus forming a feedback loop (Germain et al. 2015). The self-regulatory 
capabilities of HipBA have been accredited for the resuscitation of cells otherwise stuck 
in the inhibiting loop. The explanation is, however, challenged by the finding of 
Chowdhury et al. (2016a) that persisters are readily formed also without the presence of 
(p)ppGpp via different pathways. 
2.1.4 Stationary phase bacteria 
Studying the expression profiles of persisters in comparison with other forms of bacterial 
growth has given some insight into the nature of the dormant phenotype. Transcriptomic 
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comparisons have shown similarities between the expression profiles of persisters and 
stationary phase bacteria, although the opposite has also been demonstrated (Shah et al. 
2006; Keren et al. 2011). 
Microbial growth in a batch culture – the primary cultivating method in a laboratory – 
can be depicted as a curve that is divided into four distinguishable stages (Madigan et al. 
2012) (Figure 2). 
 
Figure 2. A typical bacterial growth curve. No growth is observed in the lag phase wherein 
bacteria are newly habituating to their environment. As the cells begin to multiply, the 
exponential phase sets in. As nutrients deplete and metabolic by-products accumulate, the 
exponential division is halted and the stationary phase starts. When enough toxic by-
products have been produced and all available nutrient sources are exhausted, the bacteria 
begin dying rapidly, which is reflected in the downward trend in the death phase.  
 
After the initial lag phase, in which the bacteria habituate into the growing conditions, 
follows the exponential phase (or log phase), where the bacteria divide without inhibition 
and grow exponentially (Madigan et al. 2012). Towards the end of the exponential phase 
the nutrients in the surrounding medium become scarce while growth-inhibiting 
metabolic products may be accumulated. This initiates the entry into the stationary phase, 
where observable growth stops as bacteria start dying at a rate that counters the already 
slowed-down division of cells. 
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Although stationary phase is not a defined physiological state but rather just descriptive 
term depicting a part of a typical growth pattern, it can be generalized that many 
characteristic changes occur as bacteria approach the environmental limit of exponential 
growth (Nyström 2004). Significant alterations in gene expression prepare the bacteria to 
survive in the aggravated conditions by radically changing the physiology and even 
morphology of the cells (Kolter et al. 1993). Bacterial cells may become smaller through 
reductive division to support the number of surviving cells without the nutrients required 
for proper growth. Cell walls may become thicker, more rigid, more adherent and less 
permeable. Overall protein synthesis is reduced, while the production of proteins essential 
for prolonged survival is up-regulated. In transition to stationary phase the bacteria 
become cross-tolerant to various environmental stressors such as heat, oxidative stress, 
osmotic challenge and toxic products (Nyström 2004). 
Importantly, persister formation is strongly induced in mid-exponential phase and the 
fraction of persisters plateaus at roughly 1 % in the early stationary phase (Keren et al. 
2004b). The expressional changes are complex, but a comprehensible connection between 
stationary phase bacteria and persisters can be made by comparing the behaviour of 
alarmones in both types of cells. The second messenger (p)ppGpp, along with cyclic di-
adenosine monophosphate (c-di-AMP) – another small nucleotide messenger present in 
Staphylococcus aureus – are strongly present also when bacteria enter stationary phase 
(Chang et al. 2002; Corrigan et al. 2015). The alarmone signalling contributes to the 
induction of the stringent response via various transcriptional and translational regulators. 
Stationary phase cultures are highly tolerant against antimicrobials, to which they again 
become susceptible upon metabolic activity induction for example by dilution in fresh 
medium (Mascio et al. 2007). This further demonstrates the increased presence of 
persisters. The connection between stationary phase bacteria and persister cells offers a 
fortunate advantage from an experimental point of view since it is straightforward to study 
simple planktonic bacteria in a liquid medium. It is, however, important to notice that 
non-growing stationary phase cells and persisters are distinguishable phenotypes (Lewis 
2007). Not all cells in a static culture are in an actual state of persistent dormancy induced 
by toxin-antitoxin modules; another fraction has only ceased dividing and will quickly 
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begin to grow again when the environmental requirements are again met (Lewis 2007; 
Germain et al. 2015). 
2.2  Biofilms 
Although having been unwittingly experimented with for decades, biofilms were 
probably first characterized in detail in 1933 by Arthur Henrici, who discovered that a 
glass slide immersed in the water of an aquarium or a lily pond would in a few days be 
covered in a uniform layer of bacteria (Henrici 1933; reviewed by Dufour et al. 2010). In 
his article of freshwater bacteria Henrici describes a dense bacterial growth that, 
supported by a filamentous morphology and a “sheath of gum”, attaches to glass slides 
tightly enough not to come loose under tap water rinsing (Henrici 1933). Even though the 
present terminology was born only later, it is quite evident that Henrici came to accurately 
depict biofilm growth complete with the microcolony morphology and the supportive 
matrix of extracellular polymeric substance.   
In his paper Henrici went on to conclude that, contrary to earlier understanding, 
freshwater bacteria are mostly living in sessile colonies attached to an underwater surface 
and not as singular planktonic microorganisms freely floating in the water (Henrici 1933). 
This conclusion has since been extended to all natural habitats by a wealth of knowledge, 
and it is today estimated that 99 % of all bacteria live naturally in biofilms (Donné and 
Dewilde 2015). 
Considered the founding father of modern biofilm research, Bill Costerton is responsible 
for the critically important induction in the 1970’s that what is true for bacteria living in 
freshwater ponds or mountain streams, has to be true for bacteria colonising a host 
organism as well (Costerton et al. 1978; Lappin-Scott et al. 2014). Costerton made 
observations of the glycoprotein polysaccharide, glycocalyx, which facilitates the 
adhesion of bacteria onto surfaces. His pioneering work on many fronts granted the 
scientific community an exhaustive understanding of biofilm structure and the process of 
biofilm formation while elucidating the role of biofilm bacteria in recalcitrant infections 
and antimicrobial tolerance and resistance.    
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2.2.1 Structure and formation 
A biofilm is created when bacteria adhere to a surface or to other microorganisms and 
form a microcolony covered in a viscous matrix of secreted extracellular polymeric 
substance (EPS) (Donné and Dewilde 2015). The extracellular matrix, taking up some 85 
% of the total biofilm composition, consists mostly of polysaccharides, proteins and 
DNA. 
The formation of a biofilm is a complex multistage process (Figure 3). It typically begins 
when planktonic bacteria transiently attach and adhere onto a surface – an event which 
itself is usually triggered by a change in the environment that calls for lifestyle conversion 
(O'Toole et al. 2000). The capabilities of different bacterial species to bind onto a surface 
differ, some being readily able to adhere to an unconditioned surface while others may 
need the assistance of the adhesion proteins of a pioneer colonizer. 
 
 
 
Figure 3. Biofilm formation scheme (modified from Monroe 2007). Planktonic bacteria 
adhere onto a surface and start developing into microcolonies. The production of EPS 
begins and the colonies become engulfed within the matrix, forming a biofilm. The 
biofilm then grows and maturates. From the mature biofilm planktonic bacteria and 
smaller microcolonies are again dispersed to complete the cycle. 
 
Subsequently other nearby planktonic bacteria – either of the same species or a different 
one – will bind the surface itself or the prior adherer to form more stable cellular aggregate 
(O'Toole et al. 2000). Intricate networks of intra- and intercellular signalling become 
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stimulated as bacteria organize to form a biofilm. Changes can be observed in cellular 
morphology, physiology and communication. The up-regulated production of 
extracellular polymeric substance gives rise to the characteristic viscoelasticity and 
sliminess within the biofilm. From the maturated biofilm bacteria will again detach into 
the surrounding liquid as planktonic cells to complete the cycle of attachment and 
dispersal. 
2.2.2 Medical challenge 
Biofilm is a microbial lifestyle commonly associated with antimicrobial tolerance and 
resistance (Van Acker et al. 2014). Living as a community inside a sticky polymer matrix 
has various assets for bacteria colonising a host (Lewis 2005). When attached, the bacteria 
are not easily swept into the surrounding medium to be readily recognized and eliminated 
by the circulating components of the host immune system. The confinement within a 
protective layer of viscous matrix gives the bacteria some protection against phagocytic 
white blood cells in the event of an immune response (Thurlow et al. 2011). Additionally, 
bacteria in a biofilm community have capabilities to attenuate the pro-inflammatory 
response e.g. by modulating cytokines and affecting the activation of macrophages. 
Conversely to the host defence components, the activity of antimicrobials is not strongly 
affected by the protective extracellular polymeric substance. Although some cationic 
antibiotics, such as aminoglycosides, may become trapped in a negatively charged matrix 
for example in the alginate rich biofilm produced by Pseudomonas aeruginosa, most are 
readily permeated inside the EPS (Hatch and Schiller 1998). Nevertheless, biofilms have 
proven to be extremely tolerant to antimicrobial treatment – a trait that makes them an 
important causative agent in various chronic infections (Lewis 2005). Naturally, many 
pathogenic bacteria have impressive arrays of antimicrobial drug resistance mechanisms 
that have evolved as a response to drug exposure, when the selection pressure caused by 
the antibiotic favours the survival of mutated strains with strategies to fight the treatment. 
The same is true with biofilms. Somewhat unexpectedly no specific and heritable 
mechanisms of drug resistance can often be found in biofilm bacteria that have regardless 
survived a treatment with supposedly effective concentrations of antimicrobials (Lewis 
2005). 
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When combined with the perks of persistence, biofilm lifestyle is astonishingly resilient 
(Lewis 2005). Characteristic for biofilm lifestyle is a pronouncedly large subpopulation 
of persisters within the community. Even with prolonged courses of antimicrobial 
chemotherapy, these bacteria prevail to be regrown safe inside the biofilm after the 
environmental stressor has passed. Biofilm persisters give rise to recalcitrant infections 
that are very difficult to eradicate.  
In persister bacteria no heritable mechanisms of antibiotic specific resistance have to be 
present. Still, the challenge of antimicrobial resistance cannot be omitted in this context. 
Bacteria constituting to relapsing biofilm infections may frequently become exposed to 
antimicrobial compounds in sub-inhibitory concentrations (Davies 2003). This can 
effectively breed resistant strains in an increased frequency. Additionally, the intra- or 
interspecies passage of mobile genetic material is rapid in a biofilm, where the highly 
heterogeneous microbial community demonstrates increased competence for 
transformation, i.e. the bacteria readily take in DNA from their environment (Madsen et 
al. 2012). Plasmid stability is also enhanced within a biofilm, which enables quick 
horizontal transfer of resistance genes. Finally, the frequency of transduction, i.e. the 
direct gene transfer between conjugated bacteria is increased in a closely associated 
population. In addition to the intrinsically tolerant nature of biofilms and the persisters 
harboured by them, antimicrobial drug resistance is another major challenge in biofilm 
infections. Targeting persisters is therefore a vital strategy to address both key challenges.  
2.3 Biofilm and persister related diseases 
Treatment-resistant infections that burden healthcare greatly are increasingly traced back 
to the presence of tolerant biofilms. Typical examples of such diseases include the lung 
disorder cystic fibrosis, the heart infection endocarditis, chronic urinary tract infections 
and chronic wounds (Costerton et al. 1999). Additionally, biofilm formation on 
indwelling medical devices is a common problem leading to costly reoperations where 
biofilm-colonized prostheses have to be replaced, for example in joints or heart valves.   
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2.3.1 Cystic fibrosis 
Cystic fibrosis (CF) is a genetic disorder that stems from a mutation in the CFTR gene 
that leads to the expression of a faulty ion-channel by the same name – CFTR or cystic 
fibrosis transmembrane conductance regulator (Schwiebert et al. 1999). This causes the 
liquid covering airway surfaces to become dehydrated making it highly viscous and 
reducing its mobility, which severely impairs lung clearance. In addition to the weakened 
mucociliary clearance, the altered composition of the airway surface liquid also hampers 
other systems of innate immunity including white blood cells and cationic antimicrobial 
peptides (Döring and Gulbins 2009). Together these deficiencies expose the diseased 
lungs to a chronic polyspecies bacterial infection with a strong biofilm involvement. 
From the viewpoint of antimicrobial chemotherapy, CF is a particularly challenging 
disease. The shortage of mechanical, cellular and chemical innate defences together with 
a niched environment with hypoxic and acidic conditions makes the disease-ridden 
airway epithelia favourable for biofilm and persister formation while significantly 
impairing drug delivery and efficacy (Høiby 2002). The prominent presence of dormant 
persister bacteria within the CF biofilm predisposes the lungs to remain infected even 
after a successful course of antimicrobial treatment (Mulcahy et al. 2010). The 
management of CF calls for repeated if not continuous antimicrobial treatments, and even 
then the recalcitrant infection is virtually ineradicable.  
Presently the median life expectancy for CF patients is about 40 years and rising 
(MacKenzie et al. 2014). Along with the development of mucolytic agents and the more 
recent breakthroughs with CFTR-receptor correcting or potentiating drugs, the improving 
outcomes in CF treatment can be attributed to newly developed enhanced antimicrobial 
therapies. Together with various combinations of conventional antibiotics administered 
orally or intravenously, the recommended antimicrobials for CF treatment are inhalable 
formulations of the aminoglycoside tobramycin and the polymyxin antibiotic colistin 
(Sherrard et al. 2014). Up to a certain point the bacterial exacerbations can be managed 
with current tools. Nevertheless, the recalcitrant nature of the infection is still too big a 
challenge for antimicrobial chemotherapy and the infection will always relapse, even 
though novel treatments are able to deliver impressive concentrations of effective 
antimicrobials directly into the infection site. This is highly suggestive of persister 
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involvement in the infection dynamics of CF: the susceptible population is killed while a 
subpopulation of persisters stays alive in a dormant state to later cause the infection to 
relapse.   
2.3.2 Tuberculosis 
Tuberculosis, an infectious disease that usually affects the lungs, is a potentially life-
threatening condition, which is typically treated with an extended course of multiple 
antimicrobials in combination (Liippo 2010). It is caused by species of the family 
Mycobacterium; most often the species M. tuberculosis. Based on its cell wall structure, 
the species belongs to a curious class in between Gram-negative and Gram-positive 
bacteria (Fu and Fu-Liu 2002). However, genetic analyses have shown that it shares more 
ancestry with Gram-negative bacteria demonstrating many characteristics of Escherichia 
coli and Pseudomonas aeruginosa. 
The need for long-term treatment with disease-specific antimicrobials has been accounted 
to the persistent nature of the disease, which is relatively well understood and a subject 
of numerous studies  (Zhang et al. 2012). Although most cases present themselves with a 
disease isolated in the lungs, tuberculosis may affect practically any organ system. 
Characteristic for tuberculosis is the presence of various secluded infection foci in e.g. 
granulomatous lesions or cavities, in which differing microenvironmental conditions (low 
pH, abnormally low or high oxygen content, and low level of nutrients) together induce 
persister conversion. In the diverse infection foci, the bacteria may exist in various states 
of dormancy, hiding out of reach of chemotherapeutics and host immune defences. This 
contributes to the often latent form of tuberculosis. 
In a disease with such optimal conditions for enabling antimicrobial tolerance, relapses 
are common especially without the strict adherence to the treatment regime, which in turn 
provokes the breeding of strains with specific heritable mechanisms of antimicrobial drug 
resistance (Liippo 2010). Indeed, extendedly drug resistant forms of tuberculosis pose a 
serious risk for general health worldwide. 
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2.3.3 Lyme disease 
Caused by the tick-borne bacterium Borrelia burgdorferi, Lyme disease (LD) is a multi-
organ infection that typically first presents itself with a migrating erythema radiating from 
the tick-bite location (Hytönen et al. 2008). The infection spreads to different tissues 
readily via blood circulation. In addition to the early skin reactions, symptoms may 
classically emerge in the nervous system and joints, along with the significantly rarer 
manifestations for instance in the heart or in the eye. The typical symptoms of 
disseminated LD include inflammatory mono- or oligoarthritis, polyneuropathy and 
problems in the central nervous system, some of which may stay lingering for months or 
even years after the infection itself has been cured (Hytönen et al. 2008; Feng et al. 2015). 
However, in most cases the disease is caught and treated with antimicrobials – typically 
a few-week course of amoxicillin or doxycycline – in such an early phase that the 
consequences are limited to the initial skin rash and possibly some flu-like symptoms. 
Still, even if treated accordingly, LD may in rare occasions become a chronic condition. 
This type of a chronic LD is becoming an increasingly popular subject of a fiery debate, 
in which the opposing sides are essentially arguing whether the lingering symptoms – 
usually of a highly subjective nature – are somatic and/or psychosomatic remnants of the 
since-cured destructive infection or a manifestation of a persistent infection that is 
somehow able to survive the intensive antimicrobial treatment and to avoid a perfectly 
competent host immune system (Wahlberg and Nyman 2009; Feng et al. 2015). Both 
arguments are probably correct, although it is very rare for the infection itself to become 
chronic (Wahlberg and Nyman 2009). 
The implications of persistence in LD have warranted numerous publications. Persister 
bacteria have been managed to isolate from animal disease models and lab cultures of B. 
burgdorferi (Straubinger et al. 1997; Feng et al. 2015; Caskey and Embers 2015). An 
especially interesting finding concerns the morphology of the bacteria in different growth 
conditions (Feng et al. 2015). In its typical form in a normally growing culture, B. 
burgdorferi is a spirochete. However, when grown for many days as a stationary phase 
culture or in otherwise stressful conditions that generally induce persister formation in 
various species, the bacteria begin to increasingly convert into a round-bodied form. 
Additionally, aggregated microcolonies reminiscent of biofilm growth start to develop as 
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the culture is aging. In a 10-day old culture, the microcolony form is the dominant 
morphology. 
The change in morphology is connected with a significant increase in antimicrobial 
tolerance and a decrease in metabolic activity (Feng et al. 2015). For all intents and 
purposes, the round-body and microcolony morphologies of B. burgdorferi are bacterial 
persisters. Moreover, when the surrounding conditions return to a favourable state the 
bacteria convert back to their spirochaetal form. The clinical significance arises from the 
notion that the aggregated microcolony forms abundantly present in a persister population 
of B. burgdorferi could indeed share some of the immunoevasive properties of a biofilm. 
This could explain the phenomenon of chronic LD infection while the non-infectious 
post-Lyme disease syndrome has been attributed to a prolonged autoimmune response 
triggered by a bacterial antigen.        
2.3.4 Infections of indwelling medical devices 
Because of the nature of microbial growth in liquid medium, biofilms tend to develop in 
the interfaces between the surface of an indwelling medical device, such as a catheter, 
and bodily fluids (Costerton et al. 1978; reviewed by Donlan and Costerton 2002; Percival 
et al. 2015). Many medical conditions necessitate the implantation of a medical device 
inside the body of a patient, where conditions are strongly favourable for biofilm 
formation on the non-living surface of the device. Indeed, indwelling medical devices 
give rise to a plethora of treatment-resistant nosocomial infections (Costerton et al. 1999; 
Percival et al. 2015). 
Urinary catheterization is probably the most common source of these infections (Nickel 
and Costerton 1992; Bryers 2008). The mechanical irritation of the bladder lining caused 
by the catheter facilitates the infection from the biofilm colonization residing on the 
tubing. In addition to the obvious problems associated with cystitis, the catheter may 
become encrusted and blocked because of the crystallization of minerals within the 
biofilm in the presence of pH-increasing bacteria (Figure 4) (Jones et al. 2006). 
Antimicrobials are routinely needed to limit the biofilm growth and control the infection. 
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Figure 4. Biofilm encrustation in a silicone urinary catheter removed from Proteus 
mirabilis -infected bladder model on blockage (left). An antimicrobial treated test catheter 
removed after 7 days of incubation is free of encrustation (right). Modified from Jones et 
al. 2006.  
 
Central venous catheters are another type of a tubular indwelling device prone to causing 
infections (Donlan and Costerton 2002; Percival et al. 2015). Because the catheter is in 
straight contact with bloodstream, host-derived proteins such as fibronectin and 
fibrinogen rapidly coat its surface, effectively facilitating bacterial adhesion and biofilm 
formation (Raad 1998). The colonization predisposes the catheterized patient to severe 
complications including embolization and sepsis. 
Implanted prostheses, for example artificial joints and mechanical heart valves, are 
similarly vulnerable to biofilm development (Costerton et al. 1999). A biofilm growing 
on a prosthetic joint may cause a severe and painful infection while leading to the 
loosening of the prosthesis from the bone it is installed into (Barberán 2006). Biofilm 
infection of a prosthetic heart valve may lead to life-threatening endocarditis (Piper et al. 
2001). Both manifestations of prosthetic biofilm infections are characteristically 
treatment-resistant and require aggressive antimicrobial therapy, possibly in combination 
with a surgical intervention and the replacement of the infected device (Piper et al. 2001; 
Barberán 2006). 
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2.3.5 Other biofilm-related diseases 
Heart valves are susceptible to biofilm infection even without preceding surgical 
operation (Mills et al. 1984). Infective endocarditis is a severe recalcitrant condition 
characterized by microbial vegetation on heart endothelia and valves. Bacteria do not 
easily attach onto endothelial tissue, but the adherence is greatly facilitated by the 
production of a glycoprotein slime that eventually engulfs the growth into a biofilm that 
is responsible for the clinical manifestation of endocarditis (Scheld et al. 1978; Ramirez-
Ronda 1978; Mills et al. 1984; Donlan and Costerton 2002). The disease damages the 
infected heart tissue and may cause infective emboli as microcolonies detaching from the 
biofilm shed to bloodstream (Donlan and Costerton 2002). Lodging of such an embolus 
inside a blood vessel can lead to serious consequences depending on the location of the 
blockade. Additionally, a persevered endocarditis can cause the infected valve to become 
calcified as minerals from the bloodstream crystallize within the biofilm (Poller et al. 
1989). As with other biofilm diseases, infective endocarditis is often profoundly tolerant 
to antimicrobial treatment and may necessitate surgical intervention (Prendergast and 
Tornos 2010). 
The microbes causing infective endocarditis typically originate in oral infection foci 
within the gingival tissue, from where they enter the bloodstream in the event of a 
disruption, for example a dental procedure (Parahitiyawa et al. 2009). Rather 
unsurprisingly, the microbial colonies in the oral environment are another example of an 
intricate biofilm system (Marsh 2006). Depending on the spectrum of species, oral 
biofilms may give rise to local infections, such as dental caries and periodontitis, the 
infection of the supportive tissue around teeth eventually leading to the destruction of the 
tissue and loosening and detachment of teeth (Sbordone and Bortolaia 2003). 
2.4 Eradicating persisters 
The previously described characteristics of persister bacteria make them a profoundly 
challenging target for any antimicrobial. However, a handful of compounds with some 
efficacy against persisters exist among the currently available antimicrobial drugs. 
Furthermore, persisters have become an important aspect of drug discovery, and a few 
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putative anti-persister agents have recently been described. Still, the scarcity of available 
and upcoming treatment options against persister diseases is worrisome.   
2.4.1 Conventional antibiotics 
Although most antibiotics are practically useless against persister bacteria, some have 
demonstrated limited efficacy (Keren et al. 2012). Long courses of high-dose rifampicin, 
an RNA polymerase inhibitor, have been shown to eradicate persister cultures in 
Mycobacterium tuberculosis (Hu et al. 2015). The proposed mechanism is that even 
though rifampicin works as a bacteriostatic antibiotic, a long time inhibition of protein 
synthesis could lead to irreversible dormancy through the disruption of the numerous TA-
modules needed for metabolic state control in M. tuberculosis (Keren et al. 2012). 
Interestingly, rifampicin is often successfully used in combination with other antibiotics 
to treat biofilm-related conditions (Jacqueline and Caillon 2014; Gbejuade et al. 2015). 
This could be due to its ability to affect the persister subpopulation within the biofilm. 
Additionally, aminoglycoside tobramycin and fluoroquinolone ofloxacin have been 
successfully used in eradicating Pseudomonas aeruginosa persisters when applied in high 
concentrations and for an extended time period (Keren et al. 2012). This type of treatment 
is especially relevant in the prevention and treatment of CF exacerbations: courses of 
inhalable aminoglycosides have been widely adopted as a treatment protocol (Sherrard et 
al. 2014). 
2.4.2 DNA crosslinkers 
Mitomycin C (MMC) (Figure 5a), an anti-cancer drug isolated from the soil bacterium 
Streptomyces caespitosus, is a compound in which anti-persister activity has been 
demonstrated both in vitro and in vivo (Kwan et al. 2015). It is a prodrug that acts as a 
DNA-crosslinking agent upon activation by enzymatic reduction, a reaction also present 
in metabolically inactive cells. 
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                               a                                                                  b 
Figure 5. The structures of MMC (a) and cisplatin (b) (modified from PubChem). 
 
By its destructive mechanism of effect, MMC does not rely on the division or metabolic 
activity of the target bacteria. Therefore, it can rapidly eradicate persisters in various 
species. However, as the current indication of the drug demonstrates, it is generally highly 
toxic to mammalian cells as well. The pronounced off-target toxicity prevents it from 
being a candidate drug for antimicrobial therapy. MMC is still highly suitable for 
experimental use, as it is very effective and fast-acting against both Gram-positive and 
Gram-negative bacteria. Additionally, it does not interfere with assays relevant to drug 
discovery, and it is even used in the validation of such assays (Invitrogen 2012).  
Based on the successful experimentation with MMC, research has been extended to 
cisplatin (Figure 4b), another FDA-approved anticancer agent with similar DNA-
crosslinking capabilities (Chowdhury et al. 2016b). As hypothesized, it proved to be 
effective against a broad spectrum of bacteria – even more active than MMC itself. 
However, the above-described limitations concern cisplatin too, since it is non-
specifically toxic towards host cells.  
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2.4.3 Resuscitation  
As the mechanisms of persister multi-tolerance are unspecific and do not rely on the 
destruction of the antimicrobial compound or keeping it from binding by altering the 
conformation of the target site, traditional antimicrobials could be used successfully if the 
persisters were resuscitated back to their metabolically active and reproductive state 
(Zhang 2014). Strategies for achieving this have been also described. 
Making the environment of the microorganisms favourable again leads to the awakening 
and metabolic activation of the persisters (Joers et al. 2010). In vitro this is easily done 
by diluting the static persister culture into fresh medium. A respective possibility in in 
vivo treatment could be to reintroduce a carbon source into the dormant culture, as 
demonstrated by Allison et al. (2011) in a mouse urinary tract model of infection. The 
group used metabolites such as glucose, mannitol and fructose to successfully re-sensitize 
E. coli persisters against aminoglycoside antibiotics. Indeed, inhaled mannitol has been 
successfully experimented with in the treatment of CF, a chronic lung disease, which is 
strongly affected by the presence of Pseudomonas aeruginosa persisters. Although its 
effectiveness in CF has been originally attributed to osmotic enhancement of liquid 
transport, it seems that mannitol is also improving the sensitivity of P. aeruginosa against 
aminoglycosides by stimulating proton motive force over the bacterial cell wall and 
increasing the metabolic activity of the bacteria (Barraud et al. 2013). However, the 
antibiotic sensitizing effect could not be replicated in a CF-lung derived epithelial cell 
line – a model more representative of in vivo conditions (Price et al. 2015). 
Persisters’ ability to wake up upon the improvement of the surrounding conditions has 
yet to be elucidated on most species. It has probably been best documented in high 
guanosine-cytosine -content actinobacteria, from which a first common resuscitation 
promoting factor (Rpf) protein was discovered by Mukamolova et al. (1998). This group 
found the protein from Micrococcus luteus and demonstrated its ability to resuscitate 
dormant bacteria of the same species, along with various Mycobacterium species. Other 
resuscitation factors have since been found to function in different mycobacteria 
(Mukamolova et al. 2002). Hints of a similar resuscitating moiety existing outside 
actinobacteria were recently observed by Pascoe et al. (2014). The group discovered that 
spent medium supernatant from Staphylococcus aureus culture could reactivate dormant 
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cells. The effect was greatly diminished by heat denaturation or trypsin digestion of the 
supernatant, which points towards the existence of a resuscitation promoting protein akin 
to those reported earlier. A small-molecule compound with the ability to resuscitate and 
resensitize E. coli persister cells has additionally been described (Kim et al. 2011). A 
novel moiety only known as C10 was demonstrably able to speed up persister regrowth 
and re-enable norfloxacin killing.  
2.4.4 Relacin, a ppGpp analogue 
A new type of an anti-persister compound recently discovered is relacin (Figure 6), a 
ppGpp analogue that inhibits (p)ppGpp synthetizing Rel enzymes (Wexselblatt et al. 
2012). According to in silico modelling, relacin tightly occupies the active site of Rel/Spo 
type of a (p)ppGpp synthetase via several bonding interactions. This inhibition leads to 
the disruption of the stringent response, which deprives the target bacteria of survival 
mechanisms such as stationary phase transition in S. aureus and sporulation in Bacillus 
subtilis. Biofilm formation was also shown to be greatly reduced. 
 
Figure 6. The structure of relacin, a ppGpp analogue (Wexselblatt et al. 2012). 
 
As the enzymes in the RelA/SpoT homologue family are highly conserved, the novel 
antibacterial compound can be expected to target an impressive array of different species 
(Wexselblatt et al. 2012). Indeed, the inhibition of both Gram-positive and Gram-negative 
Rel enzymes was confirmed in vitro. However, the group only managed to demonstrate 
24 
 
the activity of the compound against Gram-positive bacteria and proposed that the 
inability to affect Gram-negative species was probably caused by challenges in 
permeation trough the thicker cellular membrane. 
2.4.5 ADEP4 
Another recent finding for an anti-persister compound is the acyldepsipeptide ADEP4 
(Figure 7), a molecule capable of activating a bacterial proteolytic enzyme ClpP so that 
it starts functioning unspecifically (Conlon et al. 2013). In its normal state, ClpP degrades 
misfolded proteins ATP-dependently. However, once hyperactivated by ADEP4 that 
decouples the enzyme from ATP, it begins to attack a myriad of other, physiological 
proteins (Kirstein et al. 2009). This forces the cell to self-digest, which eventually leads 
to its death. Together with rifampicin ADEP4 was shown to be readily able to eradicate 
a deep-seated Staphylococcus aureus persister infection in mouse-thigh model of a 
chronic infection (Conlon et al. 2013). The model is designed to mimic the conditions in 
treatment-resistant recalcitrant infections in human.  
 
Figure 7. The structure of ADEP4 (Conlon et al. 2013). 
 
2.5 Antimicrobial drug discovery 
Despite the recent advancements described above, the arsenal of effective anti-persister 
strategies is limited. The problem is common to the field of antimicrobial drug discovery 
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in general: antimicrobial resistance in bacteria keeps advancing while the discovery of 
novel compounds has been stagnant for decades.  
Most of the antimicrobial drugs in use today arise in some from mid-20th century, a period 
frequently referred to as the golden era of antibiotics (Lewis 2012). Numerous novel 
compounds with diverse mechanisms of action were discovered over a relatively short 
time-span. Since then, the discovery work seems to mainly have been about refining the 
already existing classes of antimicrobials by making most of them via chemical 
modifications. 
Most of the success of the golden age can be accounted to Selman Waksman, who 
screened the abundant and diverse soil bacteria in search of the secondary metabolites 
with which the bacteria battle each other (Lewis 2012). Different species of Streptomyces 
bacteria proved to be a particularly fruitful source of antibiotic compounds, many of 
which are still in use as such or as (semi)synthetic derivatives with streptomycin being 
the archetypical example. Still, new antimicrobial properties are being discovered in the 
already isolated secondary metabolites of Streptomyces and other soil bacteria.  
The stagnation of antimicrobial drug discovery since the mid-nineteenth century, also 
known as the discovery void, arises from a couple of central challenges. One basic 
problem has been that of the non-culturable bacteria. It is estimated that only 1 % of all 
bacterial species can readily be cultured in laboratory conditions (Rappé and Giovannoni 
2003). It can be expected that many new classes of natural antibiotics become available 
for studying as the spectrum of explorable microbiomes extends. Another key challenge 
concerns the limitations of the discovery platforms currently in use (Lewis 2012). 
Different screening assays used in high-throughput screening campaigns tend to ignore 
e.g. compounds that do not penetrate the bacterial cell membranes and inactive pro-drugs 
with reactive, enzyme activated metabolites. The latter type of an antimicrobial drug is 
especially useful with persister bacteria, in which the limited metabolic activity is still 
sufficient to convert a harmless pro-drug into a reactive compound that non-specifically 
and permanently attacks a multitude of targets such as DNA within the bacterium. 
Fortunately, a recent breakthrough in cultivation techniques has brought major 
advancement to the screening of the previously non-culturable bacteria. Nichols et al. 
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(2010) developed a platform that allows the initial cultivation of soil-isolated bacteria to 
go through at their collection site to support further culturing in laboratory environment. 
Bacteria collected from an environmental site were planted in a microchamber array chip 
and sealed between semi-permeable membranes. The chip, coded as isolation chip or 
iChip, was then brought back to the original environment to cultivate the bacteria in the 
presence of their required growth factors to form initial colonies that were later studied 
in a laboratory. Indeed, using iChip, a new species temporarily named Elefteria terrae 
was discovered, and along it a novel depsipeptide antibiotic teixobactin produced by the 
newfound species (Figure 8) (Ling et al. 2015). Teixobactin proved to be effective against 
several multi-resistant strains of Gram-positive (but not Gram-negative) bacteria and – 
more importantly – no development of resistance was observed against the multi-targeted 
antibiotic with a unique pharmacodynamical profile.  
 
 
Figure 8. The structure of the depsipeptide antibiotic teixobactin (Ling et al. 2015). 
 
Natural products are a fundamentally attractive source for new antimicrobials (Newman 
and Cragg 2016). Over time, different organisms have developed intricate methods of 
self-defence. This development is particularly rapid and uninhibited in microbes that need 
to constantly evolve new ways to occupy their territory midst countless competing 
species. Moreover, as biofilm growth is the predominant microbial lifestyle encountered 
in the nature, antibiotics of natural origin have potentially evolved to be effective against 
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biofilms of the competitor species (Donné and Dewilde 2015). Additionally, many 
secondary metabolites of plants have properties that are interesting in the viewpoint of 
antimicrobial drug discovery (Bazargani and Rohloff 2016).   
No means of combinatorial chemistry can match the sometimes incomprehensible 
complexity of the various compounds created in such conditions, which makes the 
investigation of natural products still a viable option for drug discovery in parallel to the 
high-throughput screening of billion-molecule house libraries of compounds of synthetic 
origin.  
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3 AIMS OF THE STUDY 
The significance of biofilms and persisters in antimicrobial drug discovery is not yet 
widely recognized, and therefore very few platforms exist for such research. The aim of 
the first part of the experimental work was to establish a stable persister model to be used 
in the following experiments. The model development was supported with thorough 
validation. Assay methods for persister viability were additionally explored along with 
the validation effort to enable miniaturization and automation for the subsequent 
screening. 
The second part of the study consisted of a small-scale pilot screening with the aim to 
discover novel anti-persister agents. Diverse natural product -derived compounds were 
screened for activity against the newly-established persister model. 
For the third and final part of the study a proof-of-concept experiment was designed and 
carried out to demonstrate the effect of anti-persister compounds on biofilm persisters. 
The aim of the concluding experiment was to link the established anti-persister activity 
to the ability to prevent regrowth from a mature biofilm – an endpoint property desirable 
for a clinically successful anti-persister drug. The study aims are summarized in Figure 
9. 
Figure 9. Aims of the study. 
1. Model 
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4 MATERIALS AND METHODS 
4.1 Materials and bacterial strain 
4.1.1 Materials and reagents 
Penicillin G sodium salt, vancomycin hydrochloride hydrate, glycerol, resazurin sodium 
salt, Müeller-Hinton broth (MHB) and tryptic soy broth (TSB) were purchased from 
Sigma-Aldrich (St. Louis, Missouri, USA). Tryptic soy agar (TSA) was also purchased 
from Sigma-Aldrich and additionally from Lab M (Lancashire, UK). Phosphate buffered 
saline (PBS) was purchased from Lonza (Basel, Switzerland). The SCREEN-WELL® 
Natural Product library of 502 compounds was purchased from Enzo Life Sciences 
(Farmingdale, New York, USA). Additional MMC was purchased from Cayman 
Chemical Company (Ann Arbor, Michigan, USA) to supplement the SCREEN-WELL® 
library. Dehydroabietic acid was obtained from Wako Pure Chemical Industries (Osaka, 
Japan). Bovine serum albumin (BSA) was purchased from Sigma-Aldrch and additionally 
from Amresco (Solon, Ohio, USA). Colorimetric BrdU ELISA cell proliferation assay kit 
was purchased from Roche Diagnostics (Indianapolis, Indiana, USA). Nunclon™ Delta 
Surface polystyrene flat-bottom 96- microwell plates were purchased from Thermo Fisher 
Scientific (Nunc; Roskilde, Denmark). Absorbance and fluorescence measurements were 
carried out with Thermo Fisher Varioskan LUX plate reader (Vantaa, Finland). 
4.1.2 Bacterial strain 
Staphylococcus aureus strain ATCC 25923 was obtained from the HAMBI collection 
(University of Helsinki, Faculty of Agriculture and Forestry, Division of Microbiology 
and Biotechnology). The bacteria were stored in -80 °C as cryo-stocks suspended in a 
mixture of TSB with 20 % glycerol.   
4.2 Methods 
4.2.1 Cultivating the bacteria 
The bacteria were grown in plastic centrifuge tubes of 15 or 50 ml volume depending on 
the desired final suspension volume. TSB medium was inoculated with a pipetted aliquot 
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of the -80 °C glycerol stock in a 3:1000 ratio and incubated with 220 rpm aeration in 37 
°C. The cultures were let grow for a minimum of 18 hours to achieve static conditions. 
For viable count determination the bacteria were plated on TSA plates.  
4.2.2 Viable count determination 
The sampled bacteria were centrifuged for one minute in 10 000 rpm or roughly at 8000 
g and resuspended in sterile PBS after decanting and aspirating out the supernatant. The 
centrifugation pellets were not washed to avoid losing cells into the washing liquid. The 
resuspended bacteria were made into 10-fold serial dilutions in TSB and the dilutions 
were plated in 5 drops of 10 µl each on TSA plates. The plates were let dry with the lids 
off after which they were incubated upside down overnight in 37 °C for colony counting. 
Colonies were counted from each of the 5 drops of the countable dilutions. Viable count 
from a single drop was calculated using the formula below: 
Viable count = (Colony count × Dilution factor) / Drop volume. 
A mean CFU/ml value from the 5 drops was calculated for each dilution. The number of 
colony forming units per 1 ml was calculated from two adjacent dilutions with a countable 
amount of colonies. A mean value of the dilutions was used as the final concentration. 
Viable counts are later presented as common logarithmic units (log10). The calculation 
method gives rise to a detection limit of 2 units. An example of a plating result is shown 
below in Figure 10. 
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Figure 10. An overnight-incubated agar plate cultivated with 5 drops of 10 µl from 
subsequent 10-fold dilutions.  
 
4.2.3 Antibiotic susceptibility testing 
Minimal inhibitory concentration values (MIC) were established by an antibiotic dilution 
test. MHB stock solutions of each antibiotic with a final well concentration of 1.024 
mg/ml were made into 2-fold dilution series on a microplate (1.024 – 4.88 × 10-7 mg/ml). 
Overnight-grown pre-cultures of the bacteria were diluted 1000X and grown for 4h (at 37 
°C and 220 rpm) to achieve an exponentially growing culture. After the 4-hour incubation 
the diluted culture suspension was further diluted 100-fold to achieve a concentration of 
106 CFU/ml and transferred into the microplate with the antibiotics to a total volume of 
200 µl per well. The plates were incubated for 24 hours in 37 °C with aeration (200 rpm). 
After the incubation the plates were first inspected visually to find the wells 
corresponding to MIC concentrations. The result was then confirmed by an optical 
density measurement, which was repeated after the planktonic bacteria had been 
transferred into a clean microplate. Absorbance from two replicate wells of each 
antibiotic concentration was measured at 595 nm. Subsequently a resazurin staining was 
carried out to define metabolic activity and establish minimum bactericidal 
concentrations (MBC).  
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An inhibition percentage was calculated using the formula below: 
Inh-% = 100 × (Signalcontrol, mean - Signalsample) / (Signalcontrol, mean – Signalmedium, mean). 
Percentages of over 90 % were considered inhibitory. Similarly, a minimum bactericidal 
concentration was established for each antibiotic by calculating the inhibition percentages 
from the resazurin assay results. 
4.2.4 Validation of the persister model 
The persister model was validated by susceptibility testing using 10 × MIC concentrations 
of penicillin G and vancomycin. Stock solutions of the antibiotics were prepared in MHB. 
The antibiotics were added into 18-hour stationary phase culture tubes, and the cultures 
were sampled for viability counting at 0, 1, 3, 24, 48, 72, 96 and 120 hours of exposure 
as described above.  
A growth curve was established from the viability results. Logarithmic reduction of 
growth (LogR) values were additionally calculated for each antibiotic using the formula 
LogR = Log10 (CFU/mlcontrol) - Log10 (CFU/mltreated) 
 
4.2.5 Killing with mitomycin C 
Killing curves were established for MMC concentrations of 20 µM and 100 µM. MMC 
DMSO stock was added into 10 ml stationary phase cultures grown in plastic tubes for 
68 hours, while plain DMSO was added into a control tube. Incubation was carried out at 
37 °C with 220 rpm aeration. All of the tubes were sampled for viable counts (as described 
above) at 0, 5, 24, 48 and 72 h time points and additional 1 and 3 h samples were 
withdrawn from the MMC-treated tubes. Killing kinetics were studied from the viable 
counts of the sampled points. 
Additional comparative testing was carried out with an overnight-grown stationary phase 
culture. MMC DMSO stock was added into 2 ml aliquot to reach a 20 µM concentration 
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and incubated alongside a control in 37 °C with 220 rpm aeration. The tubes were sampled 
as previously after a 24-hour incubation.  
Finally, the efficacy of MMC (at 100 µM) was compared to that of penicillin G (1 mg/ml 
i.e. 8000 × MIC) against stationary phase S. aureus. DMSO stocks of the compounds 
were added into 3 ml aliquots of a 5-day old stationary phase culture to reach the desired 
concentrations. Tubes were then incubated for 24 hours in 37 °C with 220 rpm aeration.  
4.2.6 Metabolic activity induction 
A stationary phase S. aureus culture grown for 18 hours was diluted 1:1000 with fresh 
TSB and incubated in 37 °C with 220 rpm aeration. Penicillin G was added at 10 × MIC 
at 0 or 3 hours of growth. Samples of 1 ml were withdrawn from the treated tubes hourly 
for 5 hours and at 0 and 4 h time points from an untreated control tube as described above.  
4.2.7 Anti-persisters screening 
A screening of 26 natural compounds was carried out utilizing the Enzo SCREEN-
WELL® Natural Product library of natural products. 2 mg/ml DMSO stocks of the 
selected library compounds were pipetted into tubes with 3 ml (or, in the case of 
mithramycin A, echinomycin, chromomycin A3, coumermycin A1 and valinomycin, 2 
ml) of S. aureus stationary phase cultures to achieve a final concentration of 100 μM of 
each compound. The cultures were pre-grown for at least two days prior to 
experimentation. DMSO was added to standardize the vehicle quantity, also in a negative 
control tube. 100 μM MMC was used as a positive control. The tubes were then further 
incubated for 24 hours, after which viable counts were determined as described earlier. 
4.2.8 Biofilm regrowth assay 
S. aureus ATCC 25923 pre-cultures grown for 3 days were diluted 1:1000 with fresh TSB 
medium and incubated in 37 °C with 220 rpm aeration for approximately 6 hours until an 
optical density of 0.3. The bacteria were then again diluted 1:100 and 200 µl of suspension 
per well was transferred into a 96-microplate. The plate was further incubated for 18 hours 
to establish mature biofilms. 50 × stock solutions of the test compounds penicillin G, 
DHA and MMC were prepared in DMSO to a final plate concentration of 400 µM. After 
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the incubation the planktonic solution was aspirated off and 4 µl of the test compounds 
were added with 196 µl of fresh medium. The biofilms were treated for 24 hours and 
washed once with PBS after discarding the planktonic solution. 200 µl per well of fresh 
TSB was again added and the plate was incubated for 4 hours to assess relapse from the 
biofilm. Three replicate wells from each treatment group were then vigorously scraped to 
disperse the biofilms into the medium. The scraped wells were subsequently made into 
10-1 to 10-8 dilution series and plated in 10 µl drops on TSA to assess viability as described 
above. Another experiment was carried out with a 24-hour regrowth incubation time. 
4.2.9 Measuring metabolic activity 
4.2.9.1 Resazurin staining 
Staining with the redox dye resazurin was carried out according to Skogman et al. (2012) 
to detect and measure metabolic activity in the studied bacteria. 10 µl of resazurin 1 
mg/ml stock was added into each microplate well containing 200 µl of bacteria or medium 
control. The plate was then incubated with shaking (250 rpm) in darkness for 5 minutes 
to achieve a readily detectable concentration of the reduction product resorufin, which in 
most cases can be visually verified from the change in colour (from resazurin’s blue to 
resorufin’s pink). Fluorescence was measured with Varioskan LUX at the excitation 
wavelength of 560 nm and emission wavelength of 590 nm. A photograph of a stained 
plate is presented below in Figure 11.      
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Figure 11. A 96-microwell plate with bacterial suspension and test compounds after 
having been stained with 10 µl/well resazurin 1 mg/ml solution and incubated in room 
temperature. The outermost blue wells (columns 1 and 12) represent the medium controls, 
wherein very little reductive colour change is observed with the exception of one 
contaminated well. Bacterial suspension was added to other wells that readily turned pink 
apart from those treated with bactericidal concentrations of the test compounds (columns 
3-5).   
 
4.2.9.2 BrdU ELISA 
The assay was carried out following the manufacturer’s instructions. To obtain a 
stationary phase culture, 10 ml of TSB was inoculated with 30 µl of S. aureus ATCC 
25923 glycerol stock and incubated for 3 days in 37 °C with 220 rpm aeration. To achieve 
an exponential phase culture 3 ml of TSB was inoculated with 10 µl of glycerol stock and 
incubated for 18 hours. This pre-culture was diluted 1:100 with TSB and further incubated 
for 2,5 hours until an optical density of ca. 0.1.  
The test cultures were incubated with BrdU labeling reagent for 2 hours (37 °C) in three 
replicates of 100 µl. For a blank, 100 µl of growth medium with BrdU labeling reagent 
was used. To obtain a background value, 100 µl of bacterial suspension without the BrdU 
labelling reagent was incubated with the samples. Blank and background samples were 
made in 3 replicates as well.  
The cells were then centrifuged (300 g, 10 minutes) and the supernatant discarded. The 
bacteria were dried in 60 °C for 1 hour. DNA was fixed and denatured using a supplied 
36 
 
ethanol-based reagent. An optional blocking treatment was then carried out by adding 
200 µl of 1 or 5 % BSA dissolved in sterile PBS in the wells followed by a 30-minute 
incubation before continuing to antibody treatment.  
An anti-BrdU-peroxidase antibody conjugate was added and let bind into the denaturated 
DNA. After repeated washing the bound antibody was detected by TMD, a peroxidase 
substrate that gains a readily detectable blue colour upon donating hydrogen atoms for 
the peroxide reduction. The colorimetric measurement was carried out at 370 nm. A mean 
absorbance was calculated for the three replicates of each sample type with standard 
deviations. Blank values were subtracted from the background and sample measurements, 
and the results were compared. A photograph of a positive result is presented below 
(Figure 12). 
 
 
Figure 12. A close-up photograph from a 96-microtiter well plate after carrying out the 
BrdU ELISA protocol in whole. The strong colouration is produced by metabolically 
active bacteria from an exponential phase culture.  
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5 RESULTS AND DISCUSSION 
No standard tools or techniques exist for anti-persister drug discovery, and therefore the 
experimental part of this thesis starts from developing and validating a persister cell 
model. Results relevant for model development are presented and discussed first. The 
establishment of a stable persister model is followed by the experimentation with persister 
viability assays, one of which is selected for the subsequent pilot screening. The screening 
results are then presented and the hit compounds discussed in depth. The experiments are 
concluded by the proof-of-concept biofilm assay. Finally, recent findings and future 
prospects are discussed.  
5.1 Establishment of a stable persister cell model using stationary phase 
Staphylococcus aureus cultures 
5.1.1 Available persister isolation techniques 
There are only two general ways to establish a persister culture documented in the 
literature. Neither is typically associated with drug discovery, as instead the methods are 
mostly utilized in the research of persister physiology. The first one is a method utilizing 
fluorescence-assisted cell sorting (FACS) to isolate dormant cells according to their 
phenotype that was described by Shah et al. (2006). Bacteria are first genetically modified 
to produce unstable green fluorescent protein (GFP) alongside a ribosomal promoter, so 
that the level of GFP produced correlates to transcriptional activity. The cells are then run 
through a specialized flow cytometer equipment and sorted by the amount of emitted 
green fluorescence. The scientists demonstrated that the cells with dimmer fluorescence 
had a unique expression profile associated with the persister state and were highly tolerant 
to test antibiotics. Another, significantly more basic way to grow a persister-rich culture 
is to cultivate bacteria until they reach stationary phase (Figure 1). Persisters can then be 
isolated from the metabolically active bacteria by simply killing off the susceptible 
population, which is usually achieved by treating the culture with antimicrobials. 
Although prone to variation, this method has been successfully implemented in persister 
studies (Keren et al. 2004b; Lechner et al. 2012).                 
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The FACS method made it possible for the first time to accurately isolate persister cells 
without the interfering use of antibiotics (Shah et al. 2006). However, it is relatively 
laborious and requires both specialized equipment and a modified bacterial strain. The 
stationary phase culture method can be easily adopted to any basic laboratory 
environment without mentionable expenditures. The agent used to eliminate the 
replicating bacteria may, however, pose a challenge for further experiments. Using an 
antimicrobial drug can significantly affect the remaining bacteria by activating various 
stress responses and alter the number of persisters (especially so with the SOS-response 
triggering fluoroquinolones), as is pointed out by Cañas-Duarte et al. (2014), who 
presented an alternative take on the method based on alkaline and enzymatic cell lysis of 
bacteria. 
5.1.2 Untreated stationary phase model 
In antimicrobial drug discovery this challenge may not be as pronounced yet. We 
reasoned that it is not always necessary to wipe out the non-persisters before the treatment 
experiments as long as antimicrobial resistance is ruled out as the causative agent in 
survival by prior experimentation. Thus, the model may be simplified by removing the 
pre-treatment step. If the relative size of the susceptible population within a persister 
model culture is established, the anti-persister effect of test compounds can be 
distinguished from general antibacterial activity without the use of interfering 
antimicrobial agents. Based on its stability and convenience, the untreated, simplified 
stationary phase model was chosen for further experimentation. A summary of the 
persister models discussed above is presented here as a comparison (Table 1).  
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Table 1. A comparison of the methods of persister obtainment (Shah et al. 2006; Lechner 
et al. 2012; Cañas-Duarte et al. 2014). 
 
FACS 
Treated stationary 
phase model 
Untreated 
stationary phase 
model 
Strain pre-
requirements 
Yes (reporter gene 
transfection) 
No No 
Equipment 
needed 
Flow cytometer 
 
Wikimedia Commons, released 
for public domain 
Basic labware  Basic labware  
Workflow 1. Cultivation 
2. Flow cytometry 
cell sorting 
3. Experimentation 
1. Cultivation 
2. Pre-treatment 
3. (Purification) 
4. Experimentation 
1. Cultivation 
2. Experimentation 
 
Final isolate 
composition 
Pure isolate; cells of 
only the desired 
phenotype included 
Stationary phase 
culture with trace 
pre-treatment agents; 
susceptible cells 
excluded 
Stationary phase 
culture consisting 
largely of persisters; 
susceptible cells 
included 
Final isolate 
properties 
Stable isolate; 
expression profile 
unaltered, growth 
stage controllable 
Initial cell viability 
and expression 
profiles possibly 
affected by the 
preceding treatment; 
potentially labile 
culture 
Stable culture; 
distinct phenotypes 
of stationary phase 
bacteria and 
persisters present 
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5.1.3 Response of the persister cell model to conventional antibiotics 
The studies with the persister model began with the testing of antibiotic susceptibility. 
Minimum inhibitory concentrations (MIC) for vancomycin and penicillin G were 
established in a susceptible exponential phase culture to define suitable test 
concentrations for the persister model validation. MICs for vancomycin and penicillin G 
were determined to be 0.016 mg/ml and 0.125 µg/ml respectively. An 18-hour old 
stationary culture was exposed to 10 × MIC concentrations of the antibiotics to assess 
antibiotic susceptibility. The results of the 5-day exposure are presented below in Figure 
13. 
 
 
Figure 13. The antibiotic susceptibility of stationary phase Staphylococcus aureus culture 
treated with 10 × MIC concentrations of penicillin (circles) or vancomycin (squares). The 
untreated control culture is marked with triangles. Only average results are presented for 
simplicity, although the results were confirmed in parallel experiments. 
 
Although the biphasic killing pattern is not clearly distinguishable, our results are quite 
in line with those reported previously in persister experiments (Conlon et al. 2013). At 
the end of the experiment the concentration of vancomycin-treated bacteria is slightly 
(less than 1 logarithmic unit) lower than the control culture, whereas the culture treated 
with penicillin G is indistinguishable from the control. The stationary Staphylococcus 
aureus culture seems to be tolerant to conventional antimicrobials. 
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5.1.4 Reverting tolerance by inducing metabolic activity 
The ability of the persistent cultures to resuscitate was then confirmed by dilution 
experiments. Additionally, the change in antimicrobial susceptibility upon resuscitation 
was observed to confirm the transient nature of the multi-drug tolerance in our persister 
model. First, the resuscitation was observed in differently-aged stationary phase cultures 
(Figure 14). 
  
Figure 14. The regrowth of Staphylococcus aureus after a 1000X dilution made from an 
18-hour old culture (circles) or a 66-hour old culture (squares). 
 
The culture age difference does not impact the regrowth profile or the slope of the growth 
curve. However, since the same inoculum volume was used for both cultures, the starting 
concentrations differ leading to lower viable counts with the older culture throughout the 
observed time points.    
A determining factor of the persister phenotype is its multi-drug tolerance without 
hereditary mechanisms of antimicrobial resistance (Keren et al. 2004b). Therefore, the 
bacteria should become susceptible upon resuscitation. This was confirmed by treating a 
diluted culture with penicillin G (Figure 15).  
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Figure 15. The regrowth of Staphylococcus aureus diluted 1000X with 10 × MIC 
penicillin G added at dilution (circles). An untreated control was similarly diluted 
(triangles).  
 
When administered at the time of the dilution, penicillin G prevents regrowth and 
eradicates the bacteria to the detection limit within 72 hours. Still, after only one such 
passage, tolerant bacteria are likely to exist within the diluted culture as carryovers from 
the inoculum and as newly induced persisters (Balaban et al. 2004). 
When the bacteria are allowed to reach exponential state before starting the antibiotic 
treatment, the killing effect is not as pronounced (Figure 16). Yet, a drop in viability is 
immediately observed, and after 48 hours of exposure the bacterial counts are reduced 
significantly more than what is seen in stationary phase cultures. It can be concluded that 
dilution in fresh medium facilitates resuscitation in the stationary phase persister cultures 
and restores antimicrobial susceptibility, as expected. 
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Figure 16. The effect of penicillin G on Staphylococcus aureus culture regrown for 4 
hours after a 1000X dilution (circles). An untreated control is marked with triangles. 
 
5.1.5 Validation of the stable persister cell model with mitomycin C 
Mitomycin C (MMC) is a compound with known activity against persister bacteria 
owning to its ability to damage bacterial DNA (Kwan et al. 2015). The persistent nature 
of the stationary phase model culture was validated by comparing the efficacy of MMC 
(33 µg/ml; 100 µM) to that of a high concentration (1 mg/ml; 2800 µM) of penicillin G, 
a conventional antibiotic (Figure 17). 
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Figure 17. The effect of penicillin G and MMC on stationary phase Staphylococcus 
aureus. 
 
The anti-persister activity of mitomycin C is preserved even in a 5-day old stationary 
phase culture, whereas penicillin G has no effect despite the extremely high concentration 
tested. The results give confirmation to those published earlier by Kwan et al. (2015). The 
stationary culture is highly tolerant against a conventional antibiotic whereas the anti-
persister compound MMC retains its significant activity, reinforcing the notion that the 
stationary phase S. aureus culture is a valid persister model for further experiments. 
Next, to obtain a time-kill curve, the persistent stationary phase cultures were challenged 
to two MMC concentrations (Figure 18). 
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Figure 18. A time-kill curve of MMC 20 µM (squares) and 100 µM (circles). An untreated 
control is presented alongside (triangles).  
 
Both of the tested MMC concentrations eradicated the bacteria to the detection limit 
within the 3-day experiment. A 100 µM concentration resulted in a more rapid eradication 
especially during the first hours, and the detection limit was reached earlier. Based on the 
efficacy of MMC in these initial experiments it was selected as the positive control against 
which an anti-persister activity pilot screening of natural products was carried out. 
As observed in the regrowth experiments, the age of a stationary phase culture can affect 
its behaviour. Practical challenges of the work gave rise to the need for using differently 
aged static cultures. To further confirm the validity of the method, cultures grown 
overnight (18 hours) and for 3 days were challenged with the same concentration of MMC 
(Figure 19). 
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Figure 19. MMC activity is conserved in differently aged cultures. Cultures were grown 
for 18 hours or 3 days prior to the 24-hour exposure. 
 
The activity of MMC is similar in the differently aged cultures, which suggests that the 
persister model is stable after the initial incubation. Based on the initial antibiotic 
susceptibility results (Figure 13) and the validation made with MMC it can be concluded 
that a stationary phase S. aureus culture is a suitable model for anti-persister pilot 
screening. A time of 2 days was set as the minimum cultivation time prior to 
experimentation to ensure stability. 
5.2 Assay miniaturization 
One of the aims of the study was to establish a miniaturized assay for the screening of 
potential anti-persister compounds. An ideal method for such a screening should be rapid 
(to enable high throughput and to minimize state transitions in the bacteria studied), 
specific (to only return hits with actual persister-killing capabilities as opposed to e.g. 
agents with growth-hindering properties) and sensitive (to report a decrease in the already 
low concentration of persisters). Furthermore, it should support microwell-plate format 
to allow miniaturization. 
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5.2.1 Measuring metabolic activity 
In persister experiments the measuring of metabolic activity is useful for two different 
purposes. Firstly, metabolic activity is a useful determinant of total viability (Sandberg et 
al. 2009). A reduction in the overall cellular metabolism within a culture may indicate a 
drop in the viable count. It is noteworthy, that this is not observable by standard optical 
density measurement: the cellular debris from dead bacteria will stay in the suspension, 
so no meaningful difference in absorbance values can be observed even at dramatic 
fluctuations in bacterial viability. 
Secondly, as metabolic activity is one key determinant of persistent lifestyle, it is 
beneficial to characterize its level to become aware of the possible changes in the bacterial 
state. Before experimentation it is reasonable to verify that the working culture is indeed 
in a persister-like state of dormancy. The metabolic response for the experimental 
treatment is another subject of interest: will the bacteria be resuscitated as the population 
becomes cut down? Thus, the persister viewpoint actually introduces an unfortunate 
ambiguity for metabolic activity monitoring: an active compound may spur measurable 
metabolism within the dormant culture, or further reduce it from the already low basal 
level, which would make detection a serious methodological challenge. 
5.2.1.1 Resazurin staining 
Resazurin, a blue redox dye that gains measurable fluorescence only after being converted 
by bacterial enzymes to a pink reduction product resorufin, can be used in the 
determination of metabolically active bacteria in both planktonic and biofilm lifestyles 
(Guerin et al. 2001; Sandberg et al. 2009). Resazurin staining assay is relatively easy, 
effortless and quick to carry out, and the dye itself is safe to handle. Furthermore, 
resazurin does not severely interfere with the bacteria metabolizing it making the assay 
non-destructive. 
Here, it was attempted to develop a resazurin-based persister viability assay to establish 
a screening method. Resazurin staining was carried out alongside most experiments, 
including the antibiotic susceptibility testing of stationary phase cultures (Figure 20).  
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Figure 20. The development of metabolic activity of stationary phase Staphylococcus 
aureus cultures as determined by resazurin staining, presented with the respective viable 
counts. The cultures were treated with 10 × MIC concentrations of penicillin G and 
vancomycin. The error bars in the fluorescence measurements represent the standard 
deviation of three replicate readings.  
 
The measured fluorescence decreases over the 5-day experiment in all of the cultures 
including the untreated control. No meaningful difference can be seen between the 
different treatments, as is expected knowing that the bacterial counts were also very 
similar. The decline in the fluorescence is steep within the first hours. As the test cultures 
were only let saturate overnight (compared to the 2-3-day preceding incubations in the 
latter experiments), the metabolic activity is still diminishing in the control culture at the 
beginning. The fluorescence values were plotted logarithmically against the defined total 
viable counts to study the correlation (Figure 21).   
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Figure 21. The logarithmic bacterial concentrations of stationary phase Staphylococcus 
aureus cultures treated with 10 × MIC concentrations of penicillin G (PEN; circles) and 
vancomycin (VAN; squares) presented as a function of log relative fluorescence. An 
untreated control (CTRL; triangles) is included. Regression lines (with the least squares 
fitting), line equations and the coefficients of determination (R2 values) are presented for 
each series. 
 
The coefficient of determination (R2) is over 0.90 in all treatments indicating an adequate 
correlation between resazurin fluorescence and viable count. However, as earlier pointed 
out by Sandberg et al. (2009), this assay requires a relatively concentrated bacterial 
culture (and sufficient metabolic activity therein) to detect significant differences. This 
becomes evident when resazurin staining is carried out with the MMC-challenged 
cultures, where the viable count variation is more dramatic (Figure 22). 
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Figure 22. The development of resazurin fluorescence (triangles) in a stationary phase 
Staphylococcus aureus culture treated with 100 µM MMC as compared to the viable 
count established by plating (circles). 
  
It is apparent that the initial metabolic activity is lower because of the longer saturation 
period pre-experimentation. The fluorescence intensity stays barely over the background 
level of ca. 100 relative units throughout the test, and no fluctuation can be perceived 
despite the harsh variations in the viable count. 
The main challenge with resazurin staining is its relatively low sensitivity (Sandberg et 
al. 2009). Even though the method is linear when applied to concentrated cultures, its 
reliability may decline sharply with the decreasing number of bacteria. The intrinsically 
low metabolic activity of persister bacteria calls for linearity that extends to lower cell 
counts. However, resazurin has been successfully used in experiments with dormant 
mycobacteria, which makes it potentially usable for anti-persister activity assays at least 
with some species (Taneja and Tyagi 2007). 
5.2.1.2 BrdU ELISA 
Monitoring the incorporation of the thymidine analogue BrdU (5-bromo-2'-deoxyuridine) 
into newly synthetized DNA by enzyme-linked immunosorbent assay or ELISA is a 
method typically used for mammalian cell proliferation studies that was recently reported 
to have been successfully used in an antibacterial assay as well (Bao et al. 2015). In the 
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assay bacteria are incubated in the presence of BrdU to label the DNA synthetized over 
the incubation. The incorporated BrdU is then detected with its specific peroxidase-
conjugated antibody that upon addition of a chromogenic substrate gives rise to a 
measurable colour change relative to the degree of proliferation within the bacteria. 
As a highly sensitive, albeit a relatively labour-intensive assay BrdU ELISA could be a 
useful tool in the determination of changes in the metabolic state of non-replicative 
persister cells. With some modifications – for instance, by replacing the chromogenic 
enzyme conjugate with an existing fluorescent probe detection system – the BrdU assay 
could be made compatible with many microscopic and cytometric applications and even 
single-cell studies. 
The BrdU ELISA assay was another method applied here, in order to explore alternative 
analytical solutions for persister research. It was hoped that the method would give 
information about the minute changes in persister metabolism and viability, thus serving 
as an alternative for the labour-intensive viable count plating. It was first confirmed that 
the assay could distinguish metabolically active, exponential phase culture from a non-
growing stationary phase culture by testing the assay on two differently aged cultures 
with similar bacterial concentrations (log CFU/ml 8.24 and 7.50 for the stationary and 
exponential phase cultures, respectively) (Figure 23).  
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Figure 23. The BrdU ELISA absorbance measurements from a stationary phase culture 
(left) and exponential phase culture (right). The blank signals are subtracted. The 
horizontal line represents the background signal from stationary phase bacteria incubated 
without BrdU. The error bars depict the standard deviations of 3 (for exponential phase 
bacteria) or 2 (for stationary phase bacteria) replicate measurements.  
  
As it is evident from Figure 23, the assay can readily identify a metabolically active 
culture. The colour development by the detection reaction was immediately visible upon 
adding the substrate into the exponential phase wells. The clear distinction gives further 
validation to the persister model itself, since the difference in replicative activity is 
confirmed. Instead, the stationary phase sample only produced a slight colour within the 
incubation. Moreover, the possible signal from the non-growing sample was masked by 
the relatively high level of unspecific binding demonstrated by the background control in 
which the bacteria were incubated without BrdU. 
The probable cause for the pronounced background signal is the high number of cells 
within the mixture. The number of cells in the bacterial test suspensions is several 
magnitudes higher than that typically seen in a mammalian cell culture. With such high 
cell counts there is more area available for the unspecific (non-BrdU-dependent) binding 
of the antibody probe. Complicating things further, the cell counts cannot be manipulated 
prior to experimentation: working with dormant cultures brings the singular restriction 
that the bacteria cannot be diluted long before the testing, since it would cause them to 
resuscitate. This would lead to the induction of metabolic activity rendering the 
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measurement fundamentally meaningless. Since the basal activity level in persistent 
cultures is low by definition, the lack of sensitivity caused by the high noise is a major 
challenge to overcome before the assay can be used for persister detection.   
On the hopes to reduce the background signal, several optimization steps were 
considered. For example, BSA was added (at concentrations of 1 and 5 %) before 
applying the detection antibody to block the sites of unspecific binding. As a result, all 
signals increased, but the background signal was still equal or higher compared to that of 
the stationary phase sample (results not presented). Another option considered for 
improving the signal-to-noise ratio in the BrdU assay was the purification of the bacterial 
DNA by salt precipitation before the ELISA assay. With the bacteria and cellular debris 
excluded from the measurement there would be considerably fewer sites available for the 
unspecific binding of the probe. This could dramatically enhance the sensitivity of the 
test. For this work, however, the option of adding a DNA extraction step to the already 
labour-intensive assay was rejected for being too costly time-wise.  
At least without further adjustments, the BrdU proliferation assay is not suitable for the 
described kind of persister analysis. Still, the clear distinction between the different 
culture types is a valuable piece of information as such. 
5.2.2 Viable plate count    
The superior sensitivity of viable count plating over e.g. fluorescence-based bioassays is 
well recognized (Mariscal et al. 2009). With different dilutions the plating method can be 
adjusted to suit any bacterial concentration. Being based on colony growth, plating also 
makes an obvious differentiation between live and dead cells (Hazan et al. 2012). 
However, it is a markedly labour-intensive method, and the results take at least some 20 
hours to become readable, thus making the method unsuitable for purposes that 
necessitate a quick reaction to the current bacterial concentration. An example of such an 
experiment is the above-described monitoring of MMC killing, where the correctly timed 
administration of a follow-up treatment upon resuscitation would require knowledge of 
the present cell counts.  
An additional although unrelated concern with plating methods is that they may disregard 
another phenotype of dormancy, the viable but non-culturable bacteria (VBNC) (Li et al. 
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2014). VBNCs are viable – judging by their cellular integrity, metabolism and gene 
expression – but dormant bacteria that cannot be cultivated by routine plating methods. 
The described lifestyle bears much resemblance to the persister phenotype, but the two 
are considered distinct and coexisting based simply on their differing ability to grow upon 
plating without an additional lengthy process of resuscitation (Ayrapetyan et al. 2015). 
Because of this basic limitation the VBNC bacteria are difficult to observe and take into 
account, which may be problematic in persister studies, since the abundance of VBNCs 
can greatly surpass that of persisters (Orman and Brynildsen 2013). Still, persisters 
resuscitate and grow readily on standard agar, so the method is well suitable for the 
purpose of solely observing persister viability. 
Summarizing the pros and cons of the tested methods it becomes evident that although 
viable count plating is not ideally suited for screening, it is the best method available to 
meet the requirements of this study. It robustly provides information of differently aged 
and varyingly active bacterial cultures with significantly fluctuating cell counts, which is 
key in anti-persister compound discovery. 
5.3 Pilot screening for anti-persister activity using the stable persister model  
As pointed out in the first part of the thesis, natural products are an abundant source for 
potential new antimicrobials (Newman and Cragg 2016). Compounds for the pilot 
screening were selected from an in-house library of purified natural products with 
elucidated structures. The diverse composition of the library includes compounds from 
different classes of natural or semisynthetic products. Alkaloids, coumarins, flavonoids, 
macrolides, terpenoids and peptolides are all represented in the pilot screening along with 
additional compounds outside these main classes. The persister model cultures were 
challenged with 100 µM concentrations of the selected library compounds. 
5.3.1 Hit selection and the identified hits 
The screening results are presented below in Figure 24. According to the validation results 
the hit limit was set to 2 logs of growth reduction to exclude the possible remaining 
susceptible subpopulation.  
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Figure 24. The pilot screening results are presented as logarithmic reductions of viability. 
The culture viability and the detection limit of 2 logs determine the maximum observable 
reduction. For the positive control MMC the highest observable log reduction value is 
presented.  
 
A total of 4 out of the 27 tested compounds were able to reduce the viability of persister 
model cultures enough to be classified as hits (Table 2).  
  
0
1
2
3
4
5
6
7
8
A
n
ab
as
in
e 
H
C
l
B
er
b
am
in
e
 H
C
l
B
ilo
b
al
id
e
C
ap
sa
ic
in
C
ep
h
ra
d
in
e
C
h
ro
m
o
m
yc
in
 A
3
C
o
u
m
er
m
yc
in
 A
1
C
yt
o
ch
al
as
in
 B
D
eh
yd
ro
ab
ie
ti
c 
ac
id
D
ia
ce
to
xy
sc
ir
p
e
n
o
l
D
o
m
o
ic
 a
ci
d
Ec
h
in
o
m
yc
in
Fi
se
ti
n
G
e
ra
n
yl
ge
ra
n
o
ic
 a
ci
d
G
ib
b
e
re
lli
c 
ac
id
 (
+
)
G
lio
to
xi
n
H
el
io
tr
in
e
Li
n
co
m
yc
in
M
it
h
ra
m
yc
in
 A
M
o
n
o
cr
o
ta
lin
e
N
ar
in
ge
n
in
-7
-O
-g
lu
co
si
d
e
O
le
an
o
lic
 a
ci
d
R
et
ro
rs
in
e
R
u
b
es
ce
n
si
n
 A
U
rs
o
lic
 a
ci
d
V
al
in
o
m
yc
in
Ze
ar
al
en
o
n
e
M
M
C
Lo
g 
re
d
u
ct
io
n
Log reduction Hit limit
56 
 
Table 2. Hit compounds. Log reductions are presented together with the mean reduction 
and standard deviation of all respective MMC controls. Structures (modified from 
PubChem) and weights (MW) are additionally listed for the screened natural products. 
Compound Log reduction Structure MW 
(g/mol) 
Chromomycin A3 3.62 
 
1183.25 
Dehydroabietic acid 2.04 
 
300.44 
Mithramycin A 6.30 
 
1085.15 
Oleanolic acid 2.45 
 
456.70 
MMC 5.49 ± 0.96   
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5.3.1.1 Aureolic acids 
The pilot screening campaign included the antitumor antibiotics chromomycin A3 and 
mithramycin A from the aureolic acid class (Table 2) (O'Connor 2004). Chromomycin 
A3 and mithramycin A were originally isolated from Streptomyces griseus and plicatus 
respectively (Slavik and Carter 1975). Both compounds inhibit RNA synthesis by DNA 
intercalation (the insertion of the compound between DNA base pairs) leading to 
remarkable antibacterial (Gram-positive bacteria) and antitumor activity (O'Connor 
2004). Of the two, only mithramycin A has been approved to limited clinical use in cancer 
treatment. To the best of our knowledge, no studies of the anti-persister properties of 
aureolic acids have been conducted prior to the work described in this thesis. 
Both compounds demonstrate activity against the persister model cultures (Figure 24). 
Chromomycin A3 reduces the viable count of the treated bacteria by more than 3 
logarithmic units indicating a significant efficacy. Mithramycin A is even more effective, 
readily eradicating the bacteria down to the detection limit. In fact, its efficacy surpasses 
that of the positive control MMC in its respective round of screening. These findings 
combined with the earlier work of others on DNA-targeting compounds supports a 
generalization that bacterial DNA is a prospective target for anti-persister antimicrobials 
(Kwan et al. 2015; Chowdhury et al. 2016b). 
Obviously, any compound with unspecific activity on DNA is potentially very hazardous 
for the host as well, as can be derived from the anti-cancer treatment indication held by 
many such agents including the FDA-approved MMC and mithramycin A (Taylor et al. 
2011; Kwan et al. 2015). Directing the effect more specifically towards bacterial cells 
would probably require developing a pro-drug that remains inactive until bacterial intake 
and subsequent activation. A valuable example of such a drug is metronidazole, which 
becomes destructive only after a nitroreductase-mediated activation by anaerobic bacteria 
living in reductive niches (Knox et al. 1983). Discovering this type of an exploit with a 
more widely present, bacteria-specific activator and coupling it with the like of an anti-
persister compound discussed above could ultimately give rise to very successful new 
antimicrobials. MMC fulfils this requirement partly by being converted into its active 
form by enzymatic reduction, but the low specificity and high abundance of suitable 
enzymes also in human host takes out the advantage (Paz 2009).  
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5.3.1.2 Oleanolic acid 
Oleanolic acid (Table 2) is a pentacyclic triterpenoid compound that is found, among 
other medicinal plants, in the extracts of Salvia officinalis or sage (Horiuchi et al. 2007). 
In our experiments oleanolic acid demonstrated significant activity against the persistent 
cultures (Figure 24). It is a compound with established activity against Gram-positive 
bacteria including drug-resistant strains of S. aureus and Enterococcus faecalis (Horiuchi 
et al. 2007; Kim et al. 2015). It has additionally been reported to be effective against the 
intracellular pathogen M. tuberculosis both in vitro and in vivo (Jimenez-Arellanes et al. 
2013).  
Over a 24-hour treatment oleanolic acid reduces the viability of the test culture more than 
2 logarithmic units. The result is noteworthy, since the amount of reduction is higher than 
what was previously reported with conventional antibiotics. Moreover, based on previous 
experiments the proportion of susceptible bacteria within the culture is likely lower than 
the amount of bacteria killed, which indicates at least some level of anti-persister efficacy 
in addition to general antibacterial activity.  
The antibacterial properties of oleanolic acid seem to stem from its ability to destroy 
bacterial cell membranes with peptidoglycan hydrolase enzymes being the proposed 
target (Kurek et al. 2010; Kim et al. 2015). However, the profound effect of oleanolic 
acid against the persister-rich and non-growing stationary phase culture as seen in our 
experiments is somewhat conflicting to this hypothesis, as antimicrobials targeting 
peptidoglycan production primarily affect replicating cells with more rapid peptidoglycan 
turnover. 
The cytotoxicity of oleanolic acid has previously been assessed (Kim et al. 2015). It 
demonstrated relatively low toxicity against HEp-2 cell lines derived from human larynx. 
Moreover, due to its other medicinal properties outside the antimicrobial activity 
including anti-inflammatory, anti-hyperlipidaemic and hepatoprotective effects, it has 
been used in complementary medicine especially in Asia (Liu 1995). The tolerability of 
over 3-month term treatment further reinforces the safety of oleanolic acid for human use. 
Motivated by the positive results obtained with oleanolic acid, ursolic acid, its closely 
related structural isomer was additionally screened (Figure 25a). Ursolic acid has been 
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reported to share similar antibacterial and anti-biofilm effects with oleanolic acid (Wolska 
et al. 2010; Zhou et al. 2013; Jimenez-Arellanes et al. 2013).  
 
a 
 
b 
Figure 25. The structure of ursolic acid (a) compared to its isomer oleanolic acid (b) 
(modified from PubChem). 
 
In our experiments ursolic acid lacks the marked effect seen with oleanolic acid (Figure 
24). The pharmacological profile of ursolic acid has previously been determined to be 
very similar to that of oleanolic acid’s, which makes the established difference curious 
(Liu 1995; Wolska et al. 2010; Kurek et al. 2010; Zhou et al. 2013; Jimenez-Arellanes et 
al. 2013; Jesus et al. 2015). Their structures only differ by one methyl group (Figure 25b).   
5.3.1.3 Dehydroabietic acid 
The oleoresin-derived diterpenoid DHA (Table 2) was identified as another small-
molecule hit. It is a constituent of coniferous resin with antibacterial and anti-biofilm 
properties (Fallarero et al. 2013). In the resin it acts as a defensive agent protecting the 
plant from pathogenic processes. In the pilot screening it demonstrates significant activity 
against the model culture reducing its viability for 2 log units (Figure 24). 
The newly-established anti-persister properties complement the compound’s impressive 
activity against S. aureus biofilm previously reported by Fallarero et al. (2013). The group 
additionally characterized the non-specific mammalian cytotoxicity of DHA in parallel 
to the biofilm inhibition testing. Tested against three different types of mammalian cells, 
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the concentrations sufficient to kill half of the cells over the 24 h treatment period range 
between approximately 100 and 180 µM depending on the cell line used. A 
biocompatibility index – a value that relates the concentration sufficient to reduce 
bacterial growth for three logarithmic units to the half-lethal concentration for 
mammalian cells – was defined. The biocompatibility index of DHA was found out to be 
around 1 with two out of the three cell lines, which nevertheless indicates a favourable 
balance between the antibacterial efficacy and non-specific toxicity. 
To proportion the anti-persister activity of DHA to the formerly determined anti-biofilm 
properties, additional testing with more concentrated DHA was carried out (Table 3).  
 
Table 3. The activity of 2 different DHA concentrations against the persister model 
culture. 
DHA concentration Log reduction 
400 µM  4.30 
100 µM 2.04 
 
Since the 3-log-reducing DHA concentration in these persister experiments can be 
reasoned to fall between the tested 100 and 400 µM, the corresponding biocompatibility 
index can be expected to be similar to that reported earlier (Fallarero et al. 2013). In 
contrast to the highly toxic aureolic acids and MMC, DHA is plausible in terms of 
biocompatibility making it a potential antibacterial lead compound, paving the venues for 
further exploration. 
5.3.2 Evaluation of the pilot screening campaign 
The pilot screening was able to provide several interesting hits despite its limited scale. 
In addition to identifying the profound anti-persister properties of DNA-intercalating 
aureolic acids, the screening produced two distinct hits, DHA and oleanolic acid, with 
relatively low non-specific cytotoxicity. Differing mechanisms of effect are demonstrably 
not omitted, which is an additional benefit of the chosen method. 
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The stationary phase model was stable enough to enable timely flexible workflow, 
although further normalization of the pre-growth time could aid in improving the 
moderate variability that is seen with the positive controls. The persister model culture 
was easily adapted for the screening use, since no additional treatments were required. 
The most important drawback of the pilot screening was the lack of miniaturization and 
automatization options. Plating and colony counting is labour-intensive manual work. 
This severely limits the throughput of the screening. Establishing a microplate-based 
bioassay with an endpoint that is measurable with an automated plate reader is essential 
for further screening campaigns.  
5.4 Biofilm regrowth inhibition 
To assess the main cause of the medical challenge associated with persistence, an assay 
was developed to test the ability of a range of natural products to reach and kill the 
persister bacteria residing within the confines of a biofilm. The matured 18-hour old 
biofilms were treated and the growth medium changed to see whether the films now 
ideally devoid of any living bacteria could seed new growth in the fresh broth. In a way 
the experiment simulates the conditions in a deep-seated infection, where antimicrobial 
treatments one after another wipe out the susceptible population just for the surviving 
persisters to recolonize the infection site every time. 
For the proof-of-concept experiments MMC, penicillin G and the screening hit DHA were 
tested for the activity to prevent regrowth. The viable counts obtained by scraping the 
biofilms to loosen the bacteria within the incubated medium are presented below in Figure 
26. 
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Figure 26. The 4-hour regrowth of Staphylococcus aureus from treated biofilms. From 
left to right: the untreated control, penicillin G 400 µM, DHA 400 µM and MMC 400 
µM. The error bars represent the standard deviations of three wells plated in replicate.   
 
As expected, penicillin G has very limited capability to prevent regrowth from the 
biofilms with only a 1-log reduction in the viable count compared to DMSO control. On 
the contrary, DHA is able to cause an impressive 4-log reduction that is in line with the 
previously presented results obtained from the stationary phase culture experiments and 
the earlier reports of the compound’s anti-biofilm properties (Fallarero et al. 2013).  Still, 
the observable amount of regrowth indicates that some persisters survived the treatment 
within the biofilm. Instead, the anti-persister model compound MMC seems to have 
eradicated persister bacteria and thus prevented regrowth completely. The expectedly 
opposing results with penicillin G and MMC serve as a validation for the assay.  
The results obtained from this experiment suggest applicable validity, and as a proof-of-
concept assay for overcoming biofilm tolerance the regrowth test is successful. However, 
this biofilm regrowth assay is not without drawbacks. It was observed that unspecific 
growth became observable within a 24-hour incubation. Additionally, the washing of the 
wells before replacing the medium over the treated biofilms was not sufficient to remove 
all of the test compound from the wells. The retention was evident in the MMC-treated 
wells, as the strongly coloured compound left visible deposits within the biofilm that were 
not removable by washing. A photograph of the washed biofilms with MMC deposits is 
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presented below in Figure 27. Compound carryover from the treatment can attribute to 
some of the growth inhibition in the final regrowth step of the assay, thus masking the 
real persister-eliminating effect and giving rise to possible false positives. In summary, 
the biofilm regrowth assay is a clinically relevant platform capable for recognizing true 
anti-persister compounds, but further optimization is required before moving on to routine 
screening.  
 
Figure 27. A close-up photograph taken of the bottom of a 96-microwell plate. The 
biofilms on the bottom of the wells have been washed with phosphate buffered saline 
after a 24-hour treatment. Coloured MMC deposits can be observed within the biofilms. 
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5.5 Future prospects of anti-persister drug development 
5.5.1 Evaluation of recent discoveries 
5.5.1.1 ADEP4 
ClpP as a novel and unique target for antimicrobial activity makes ADEP4 a particularly 
interesting finding (Conlon et al. 2013). However, the ADEP4 molecule is too large to 
penetrate the outer membrane of Gram-negative bacteria, which significantly limits its 
spectrum (Cain 2013). Another, more definitive challenge possibly reducing the 
therapeutic potential of ClpP as a drug target, is that the enzyme is conserved from 
bacteria to mammalian cells (Gispert et al. 2013). In eukaryotic cells ClpP is a 
mitochondrial peptidase with important regulatory functions. An NCBI VAST+ analysis 
suggests a significant structural similarity between the human ClpP and the homologous 
counterpart of S. aureus NCTC 8325, with a 0.77 Å root-mean-square deviation of 
atomic positions and 1225 spatially aligned residues with 53 % sequence identity 
(Panchenko and Madej 2004; Madej et al. 2014). This raises the question of possible 
adverse effects in the form of off-target toxicity. The superposition of human and S. 
aureus ClpP domains is presented below (Figure 28). 
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Figure 28. A 3D superposition of the common domains of human and Staphylococcus 
aureus ClpP enzyme. The result of an NCBI VAST+ similarity analysis (Madej et al. 
2014) as visualized in the Cn3D viewer (Wang et al. 2000).  
 
Furthermore, the peptide structure of ADEP4 makes it problematic in the formulation 
point of view. The possibilities of oral administration are highly limited, since digestive 
enzymes will disintegrate the therapeutic molecule quickly as it enters the stomach. As a 
therapeutic agent ADEP4 would have to be given parenterally. Topical usage is still 
highly relevant in treating wound infections, and the possible side-effects can be 
mitigated if systemic absorption is low.  
The anti-persister activity of ADEP4 is nevertheless an immensely promising discovery, 
as chronic, increasingly drug-resistant infections caused by S. aureus are a serious threat 
frequently encountered in hospital environment. Being a multi-targeted protease in its 
decoupled form, ClpP is in itself an interesting target for anti-persister drug action. 
5.5.1.2 Relacin 
The ppGpp analogue relacin does not share the probable caveat of off-target toxicity, as 
RSH proteins have no homologous counterparts in mammals (Wexselblatt et al. 2012). 
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Additionally, its mechanism of effect does not exclude Gram-negative bacteria, although 
the permeation through the Gram-negative outer membrane remains a challenge. The 
bacteria-specific but potentially broad-spectrum activity of the ppGpp analogue is a 
desirable property, as many of the most treatment-resistant and severe nosocomial 
infections are caused by Gram-negative bacteria (Kang et al. 2005). Furthermore, the 
relatively small size of the relacin molecule grants a good starting point for drug 
formulation, although it has several easily hydrolysable functionalities. In summary, 
relacin is a plausible drug candidate to begin with. 
5.5.1.3 Resuscitation 
It is possible that the breakthrough in combatting persisters is not another antimicrobial 
compound but instead an agent capable of resuscitating the dormant, tolerant bacteria. 
Upon the induction of metabolic activity within the persistent culture the actual 
eradication treatment could be picked from the spectrum of existing antimicrobials 
according to the genotypic susceptibility of the strain. The preliminary success of 
persister resensitization by reintroducing a carbon source is promising, although the 
results have been inconsistent depending on the type of model used (Allison et al. 2011; 
Barraud et al. 2013; Price et al. 2015). 
Similarly inspiring is the discovery of C10, a selectively acting small-molecule stimulant 
of persister reactivation (Kim et al. 2011). Interestingly, C10 was found to first reduce 
the viable count in the persister culture before inducing resuscitation and enabling 
norfloxacin killing. Therefore, another interpretation of the presented results is possible. 
Since C10 considerably thinned out the persister population before enacting the observed 
reactivation and the associated sensitization, the resuscitation could have been purely due 
to the change in the population dynamic. The killing of a substantial fraction of the cells 
would reintroduce carbon source into the culture upon the collective bacterial lysis, and 
this release of nutrients could potentially be enough to bring upon resuscitation. 
Such a resuscitation-by-killing treatment was experimented with in this study by 
combining an initial MMC exposure to a follow-up treatment with penicillin G. MMC 
was able to stimulate moderate regrowth (Figure 18) and penicillin G was administered, 
but all bacteria were eliminated to the detection limit regardless of whether follow-up 
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treatment was carried out (results not presented). The experimentation with a combination 
treatment was complicated by the lack of tools for the real-time determination of viability; 
by the time the regrowth was observed and penicillin G administered, MMC had already 
reverted the regrowth and killed all bacteria. The combination treatment is nevertheless a 
potential approach, which deserves further research as soon as a quicker viability assay 
becomes available.  
The increasing understanding of the mechanisms governing resuscitation in bacteria gives 
another approach to persister resensitization. Resuscitation factors have been discovered 
and characterized in depth in actinobacteria (Mukamolova et al. 1998; Mukamolova et al. 
2002). Indications of similar proteins have been observed in Staphylococcus aureus as 
well (Pascoe et al. 2014). If such a resuscitation promoter could be utilized in a drug 
discovery perspective, it could offer new ways to tackle persisters. For example, inducing 
the resuscitation protein could revert the tolerance in persister subpopulation. However, 
the described tactics of resensitization through resuscitation have the inherent hazard of 
being potentially able of waking up latent pathogens unintentionally. A safer alternative 
course of action could be to inhibit such resuscitation promoting factors instead 
(Kaprelyants et al. 2012). Keeping the persister pathogens from waking up for long 
enough could turn the advantage around and lead to eradication. This mechanism of 
action is already implied in long-course rifampicin, which supposedly causes irreversible 
dormancy by disrupting regulatory TA modules (Keren et al. 2012).  
5.5.1.4 Teixobactin and the unculturables 
Many of the most successful antimicrobials are derived from soil microbiota, and there is 
no reason to believe that the resource had become exhausted (Rappé and Giovannoni 
2003; Lewis 2012). The iChip method for one can be expected to produce more of 
interesting lead compounds after teixobactin, its proof-of-concept realization (Ling et al. 
2015).  
As a novel, multi-targeted antibiotic teixobactin is an inspiring finding, although no 
studies have been conducted on its activity against persister bacteria (Ling et al. 2015). 
Similarly to ADEP4, teixobactin also lacks the activity against Gram-negative bacteria, 
which is a major limitation. In any case, it can be expected that the associated 
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breakthrough in antimicrobial drug discovery platforms will benefit the battle against 
persisters tremendously. 
5.5.2 Cationic antimicrobial peptide derivatives 
Another class of compounds that may well become essential in tackling the persister 
challenge are the cationic antimicrobial peptides and their peptidomimetic derivatives. 
Antimicrobial peptides are a diverse group of oligo- and polypeptides that are 
encountered in all organisms as a vital and conserved part of their innate immunity 
(Hancock 2001). Cationic antimicrobial peptides target cellular membrane integrity and, 
upon permeation, various intracellular targets, while also interacting with other 
components of the host immune system. They are being studied as potential new 
antimicrobial compounds because of their many useful activities. 
The key mechanism of the bactericidal effect of cationic peptides is the permeabilization 
of bacterial membranes (Hancock 1997). The peptides, amphipathic by nature, target the 
negatively charged cell membranes of bacteria with their positively charged residues, 
which leads to pore formation and the subsequent, rapid death of the target organism. 
Conversely to conventional antimicrobials targeting the peptidoglycan metabolism within 
the cell walls of metabolically active bacteria, the membrane-disrupting effect of cationic 
antimicrobial peptides does not rely on peptidoglycan metabolism. Their activity should 
therefore be sustained against persister bacteria as well. Indeed, cationic antimicrobial 
peptides were demonstrated to quickly kill persister bacteria in both planktonic cultures 
and biofilms while potentiating the effects of conventional antibiotics (Chen et al. 2011). 
Fortunately, the powerful mechanism is quite specific towards bacteria, as eukaryotic cell 
membranes have lower potential and lack the profound negative charge (Hancock 1997).  
As discussed previously with regard to peptides as antimicrobial drugs, they have some 
important drawbacks. Peptides are readily degraded by digestive enzymes in the 
gastrointestinal tract, and the manufacture of such large and intricate molecules is 
additionally both challenging and costly (Hansen et al. 2010). To address this challenge, 
Hansen et al. (2010) developed an assortment of peptidomimetics – small-molecule 
equivalents of the minimal pharmacophore of select short antimicrobial peptides. The 
newly synthetized peptidomimetics demonstrated significantly improved enzymatic 
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stability and low toxicity against human erythrocytes while maintaining impressive 
antibacterial activity against both Gram-positive and negative bacteria (S. aureus and E. 
coli respectively). Antimicrobial peptides show great promise in battling treatment-
resistant infections, and their putative anti-persister qualities in particular warrant further 
research. 
5.5.3 Dehydroabietic acid 
Combined, the newly discovered anti-persister properties and the previously established 
anti-biofilm activity of DHA together with its relatively low toxicity bring some 
interesting implications. Coniferous resin, of which DHA is one main constituent, has 
been a subject of medical research based on its traditional usage in folk medicine to heal 
wounds and skin infections (Rautio et al. 2007; Sipponen et al. 2008; Sipponen et al. 
2012). Resin salve from Norway spruce (Picea abies) was shown to be effective in the 
treatment of infected surgical wounds and pressure ulcers, both of which are characterized 
by the presence of a recalcitrant biofilm infection (Sipponen et al. 2008; Sipponen et al. 
2012; Trøstrup et al. 2013). The efficacy of resin salve against wound infections that are 
typically tolerant to more conventional antimicrobial interventions hints towards its 
ability to overcome the biofilm persister challenge. 
This adds to the value and credibility of the results obtained in the pilot screening. 
Furthermore, the approval of coniferous resin salve for medicinal use and the success of 
the product speaks for not just the activity but a favourable tolerability as well. The topical 
administration further limits the potential toxic effects of resin constituents with 
symptoms of resin hypersensitivity being the only side-effect reported in the product 
leaflet of a commercial product derived from the experimental salve (Repolar Oy 2013). 
An important drawback seen with DHA as well is its lack of activity against Gram-
negative bacteria, which limits its spectrum (Manner et al. 2015).  
5.5.4 Novel screening methods 
Judging by the lack of success with the described bioassays outside the golden standard 
of viable count plating, it is evident that the need for more suitable screening methods 
persists. Fortunately, the spectrum of available putative methods is not limited to the ones 
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tested at this time. A successful high-throughput screening of anti-persister antimicrobials 
may only depend on finding a proper assay.  
5.5.4.1 Thioflavin T 
Used characteristically for the detection of amyloid fibrils, the fluorescent probe 
thioflavin T has recently been ingeniously adopted for the detection and quantification of 
transcriptional activity (Sugimoto et al. 2015). Based on the discovery that, in addition to 
amyloid structures, thioflavin T upon binding fluoresces with nucleic acids – especially 
with RNA – the group proposed a simple and versatile method for observing mRNA 
synthesis and monitoring metabolic activity even in real-time. By incubating the cells 
with thioflavin T and subsequently carrying out a fluorescence measurement, it was 
possible to quantitatively detect RNA, as the fluorescence intensity is relative to its 
amount. The method was further validated for studying persister-state transformations 
with a reporter E. coli strain and tested for general growth phase detection for various 
other bacteria both Gram-negative and Gram-positive. 
Since the fluorescence intensity of thioflavin T depends on its binding to an RNA 
molecule, the method does not require washing steps before making the measurements, 
and it is compatible for microscopic single-cell studies as such (Sugimoto et al. 2015). 
Additionally, the reagent itself is economical to obtain. Based on the preliminary findings 
thioflavin T seems to be a promising addition for the metabolic state determination and 
quantification of persister bacteria.       
5.5.4.2 Start growth time 
Trying to develop a viability determination method applicable for high-throughput 
screening, Hazan et al. (2012) developed an assay based on the notion that the time it 
takes for bacteria to reach a set threshold amount of growth is proportional to the initial 
viable count in the inoculum. Monitoring this time by optical density measurement and 
comparing it to a previously established calibration data made it possible to accurately 
predict the sample viable count in a couple of hours and, more importantly, on a 96-
microplate format.  
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The described start growth time assay supposedly takes persister bacteria into account 
and is suitable for viable count determination regardless of the bacterial concentration 
(Hazan et al. 2012). However, the method may be limited by the intrinsically varying 
characteristic regrowth delays of persisters and stationary phase bacteria (Balaban et al. 
2004). In a persister-rich culture this might have a significant effect on the start growth 
time. Still, the simple and elegant method seems highly promising when used in 
appropriate conditions. 
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6 CONCLUSIONS 
In the thesis it was demonstrated that stationary phase Staphylococcus aureus is a suitable 
model culture for anti-persister drug screening. The culture stays sufficiently stable after 
the initial incubation and demonstrates metabolic inactivity and antimicrobial tolerance – 
the key properties of persistent phenotype – consistently. As expected, both features are 
revertible by dilution in fresh medium. Despite rapidly developing tolerance against 
conventional antibiotics, the stationary phase culture stays susceptible to mitomycin C 
(MMC), an established anti-persister model compound.  
New compounds were identified as potential anti-persister agents by a pilot screening. 
Chromomycin A3 and mithramycin A exhibit significant activity against the model 
culture, the latter actually matching or even surpassing that of MMC the model 
compound. All three share a similar DNA-damaging mechanism that is responsible for 
the general cytotoxicity of the compounds. Whereas these novel findings are not any more 
suitable antimicrobial drug candidates than MMC owing to their harmful off-target 
effects, their activity supports the notion that bacterial DNA is a putative target for anti-
persister drug action. Further research is necessary to find ways to overcome the 
mammalian cytotoxicity while exploiting this mechanism. On the contrary, the plant-
derived screening hits dehydroabietic acid (DHA) and oleanolic acid show more promise 
from drug discovery perspective as such, despite their lower activity. Based on earlier 
reports, both are relatively well tolerated and have been used in traditional medicine. 
Moreover, the small-molecule compounds are flexible starting points for chemical 
derivatization and formulation. 
We have additionally designed a proof-of-concept trial to piece together the anti-persister 
activity of a compound and its ability to sterilize a biofilm. Based on bacterial regrowth 
from a treated biofilm, the assay mimics the conditions seen in a relapsing treatment-
resistant infection. Whereas a conventional antibiotic expectedly fails to affect a mature 
biofilm, DHA significantly reduces regrowth in a given time frame and MMC prevents it 
completely. On the basis of what is known of biofilm tolerance, the previously established 
anti-biofilm properties of DHA may partly be due to its newly identified anti-persister 
properties. 
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Streamlining the measurement of persister viability is a challenge yet to be addressed. 
Resazurin staining and BrdU ELISA are techniques worth further exploration, but at the 
time being neither is suitable for persister assays. Viable count plating is a robust method 
that lacks the automation and miniaturization options that are prerequisite for a larger-
scale screening campaign. Promising new assay methods are nevertheless being 
introduced as persister research is gaining momentum. Based on the success of even the 
limited scale pilot-screening, building an effective screening campaign for natural 
products on a novel assay could give rise to numerous new anti-persister leads.  
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8 ANNEX 1 
Table 1. The screened compounds (all structures modified from PubChem). 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Anabasine HCl 
198.69 
 
0.53 
Berbamine 2 HCl 
645.18 
 
0.15 
Bilobalide 
326.30 
 
-0.04 
86 
 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Capsaicin 
305.41 
 
0.44 
Cephradine 
349.40 
 
0.03 
Chromomycin A3 
 1183.25 
 
3.62 
Coumermycin A1 
1110.08 
 
0.11 
87 
 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Cytochalasin B 
479.61 
 
0.19 
Dehydroabietic acid 
300.44 
 
2.04 
Diacetoxyscirpenol 
366.41 
 
-0.11 
Domoic acid 
311.33 
 
0.02 
88 
 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Echinomycin 
1101.26 
 
1.30 
Fisetin 
286.24 
 
0.17 
Geranylgeranoic acid 
  
 304.47 
 
0.91 
Gibberellic acid (+) 
346.37 
 
0.25 
89 
 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Gliotoxin 
326.39 
 
0.03 
Heliotrine 
313.39 
 
-0.10 
Lincomycin 
406.54 
 
-0.14 
Mithramycin A 
1085.15 
 
6.30 
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Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Monocrotaline 
325.36 
 
-0.04 
Naringenin-7-O-
glucoside 
434.39 
 
0.03 
Oleanolic acid 
456.70 
 
2.45 
Retrorsine 
351.39 
 
-0.02 
91 
 
Compound name Molecular 
weight 
(g/mol) 
Structure Log 
reduction 
Rubescensin A 
 364.43 
 
0.15 
Ursolic acid 
 456.70 
 
0.26 
Valinomycin 
1111.32 
 
1.93 
Zearalenone 
318.36 
 
0.06 
 
